Benefits or costs? The effects of diversification with cross-industry knowledge on corporate value under crisis situation

Zhi Li, Jiuchang Wei, Dora Vasileva Marinova and Jingjing Tian

Abstract

Purpose - This paper aims to explore the explanations of "information effect" and "agency effect" of corporate diversification with cross-industry knowledge under a crisis situation.

Design/methodology/approach - Based on an event study of 203 public companies' crises in China between 2008 and 2018, the authors verify the information and agency effects of corporate diversification under a crisis situation by, respectively, examining the effects of interactions of corporate unrelated diversification with corporate transparency and knowledge deficiency attribution on the stock market's responses to the crises.

Findings - It is found that corporate unrelated diversification serves as a buffer in protecting firm value while attribution of knowledge deficiency can be a burden. The buffering effect is stronger when the corporate transparency is higher but weaker when the crisis is attributed to be caused by corporate tacit knowledge deficiency.

Practical implications - Unrelated diversified firms should strengthen information communication with stakeholders so as to break down the stakeholders' cross-industry knowledge barriers, and thus protect their own value at the crisis' onset. Also, they can further buffer the loss by reducing stakeholders' perceptions of the corporate tacit knowledge deficiency revealed in the crisis.

Originality/value - This study is the first to illustrate that the information and agency effects of corporate diversification strategy can be partially explained under a crisis situation, which provides meaningful insights about how firms can conduct knowledge management in their daily operations to deal better with

Keywords Crisis management, Corporate transparency, Cross-border knowledge, Knowledge deficiency attribution, Unrelated diversification

Paper type Research paper

1. Introduction

A persistent concern within the strategy and knowledge management literature is the effect of corporate diversification on the firm value in corporate daily operations (Aggarwal and Samwick, 2003; Ataullah et al., 2014; Berger and Ofek, 1995). Agency theory highlights the interest conflicts between managers and shareholders when it comes to strategic decisions, such as those related to corporate diversification (Ataullah et al., 2014; Denis et al., 1999). Top managers implement diversification strategies usually at the expense of the interests of the firm and its stakeholders to benefit themselves, which constitutes part of the firm's residual costs (Aggarwal and Samwick, 2003; Jensen and Meckling, 1979) [1]. Therefore, compared with focused firms, diversified firms are usually sold at a discount price (Berger and Ofek, 1995). This effect is called the "agency effect" of corporate Zhi Li is based at the University of Science and Technology of China, Hefei, China. Jiuchang Wei is based at the Department of Business Administration, School of Management, University of Science and Technology of China, Hefei, China, and School of Public Policy and Management, Tsinghua University, Beijing, China. Dora Vasileva Marinova is based at Curtin University Sustainability Policy Institute, Curtin University, Perth, Australia. ingjing Tian is based at Defective Product Administration Center, China's State Administration for Market Regulation, Beijing, China.

Received 26 November 2019 Revised 19 April 2020 31 May 2020 5 July 2020 Accepted 10 July 2020

This research was funded by the National Natural Science Foundation of China (71828102, 71921001, and 71522013), and the Foundation of President of China National Institute of Standardization (282019Y-6772), and the USTC Funding for Featured Liberal Arts (YD2160002006) and Science and Technology Planning Project of State Administration for Market Regulation (2019MK121).

diversification (Ataullah et al., 2014, p. 228). There is, however, other literature that presents an alternative view, arguing that there is not necessarily an interest conflict between managers and shareholders in diversification strategic decision making (Davis et al., 1997). The purpose of diversification strategy implemented by managers may be to gain diversification benefits, including scope-economy (Berger and Ofek, 1995), risk decentralization (Chen and Keung, 2018), and thus increase the firm value (Ataullah et al., 2014). However, due to the information asymmetry caused by diversification, external stakeholders tend to underestimate the firm value (Ataullah et al., 2014; Davis et al., 1997). This effect is called the "information effect" of diversification (Ataullah et al., 2014, p. 228). Hence, the "agency effect" explains how the diversification strategy destroys the firm value from the perspective of residual costs (Ataullah et al., 2014), while the "information effect" emphasizes the critical role of information in revealing the diversification benefits for the firm value (Hadlock et al., 2001). In this study, we unbundle some of the benefits and costs associated with diversification under a crisis situation and further investigate how corporate diversification with cross-industry knowledge affects corporate market value at the crisis' onset.

Being a negative event which shatters the overall favorable impression about a firm, a corporate crisis (e.g. a financial fraud event, product recall) is likely to trigger negative media reports (Zavyalova et al., 2012), generate extensive negative perceptions (Coombs, 2007) and pose financial and non-financial threats to the firm and its stakeholders (Wei et al., 2017). Although existing literature has carried out extensive discussions about the impacts of corporate diversification on the firm value in daily operations, only a few studies have explored its impacts under a crisis situation. We speculate that, under a crisis situation, the agency and information effects of diversification on the firm value may also be revealed. More specifically, based on the "information effect," diversification, especially unrelated diversification, enables the firm to develop specialized cross-industry knowledge (Ataullah et al., 2014), which may constitute a barrier for external stakeholders to understand the benefits of diversification strategy to the firm value (Aoki, 2010). Similarly, at the crisis' onset, the uncertainty about the firm among its stakeholders is high (Wei et al., 2017). The failure of stakeholders to understand the diversification strategy may affect their perceptions of its impacts on the firm value. Based on this, the crisis situation may bring to light the "information effect."

On the other hand, the "agency effect" implies that shareholders usually hold the top managers often benefit themselves at the expense of the firm's interests when they implement diversification strategies (Aggarwal and Samwick, 2003). Corporate crises are usually caused by top managers' self-serving behaviors (Connelly *et al.*, 2016; Coombs, 2007), such as financial fraud events (Staubus, 2005). In this case, the crisis' cause may also influence stakeholders' perceptions of the diversification strategy's impacts on the firm value at the crisis' onset. The "agency effect" may be thus revealed in a crisis situation.

Based on empirical evidence about diversification of cross-industry knowledge, corporate transparency and attributions of knowledge deficiency, this study investigates the following three important questions to test above conjectures. First, will unrelated diversification affect the firm value at the crisis' onset? Second, will corporate transparency affect stakeholders' perception of the benefits of unrelated diversification to the firm value? Third, will the attribution of corporate knowledge deficiency affect the firm value and the stakeholders' perception of the benefits of unrelated diversification to the firm value? Our findings show that the "information effect" and "agency effect" of unrelated diversification can be partly explained under a crisis situation.

Section 2 outlines the theoretical background for this study. This is followed by a presentation of the four hypotheses in Section 3 and introduction of the methods, data and empirical results in Sections 4–6. Section 7 discusses the findings and puts forward the implications, conclusions and limitations from this research.

2. Theory background

A corporate crisis represents a situation in which "stakeholders believe that the default social codes of the stricken organization are violated" (Yu et al., 2008, p. 454). Therefore, stakeholders actively seek information about the affected firms to address the cognitive dissonance caused by the crisis, and may subsequently adjust their assessment of the firms (Wei et al., 2017). Previous studies have shown that stakeholders rely on their social perceptions when interacting with an organization (Ataullah et al., 2014; Bundy and Pfarrer, 2015). For example, external stakeholders respond to a firm's insider-trading crisis according to their perceptions of corporate diversification (Ataullah et al., 2014). We, thus, assume that corporate diversification, as a significant component of the stakeholders' perceptions of an organization (Aoki, 2010), may play a key role in influencing stakeholders' responses to a crisis.

2.1 Unrelated diversification

Corporate diversification has been widely investigated by strategic management researchers (Ataullah *et al.*, 2014; Denis *et al.*, 1999; Jacquemin and Berry, 1979). There are many methods to measure it, such as entropy measurement (Jacquemin and Berry, 1979), Blau coefficient (Blau, 2001) and specialization ratio (Grant and Jammine, 1988). The most popular method is entropy measurement introduced by Jacquemin and Berry in 1979, which divides corporate diversification into related and unrelated (Jacquemin and Berry, 1979). Related diversification refers to the concentration level of firms operating in related industries (e.g. refrigerator and air conditioner manufacturing industries), while unrelated diversification describes the corporate participation level in unrelated industries (e.g. food growing and transportation industries) (Chen and Keung, 2018).

Based on the core assumption of resource dependency theory (RDT), it is impossible for any organization to obtain all resources it needs internally from itself (Pfeffer, 1972). Organizations thus need to function and survive by resource interactions with factors (e.g. other organizations) in the environment on which they depend (Pfeffer, 1972; Pfeffer and Nowak, 1976). That is, organizations are "constrained and affected by their environment and act to attempt to manage these resource dependencies by setting up different forms of interorganizational arrangements" (Pfeffer and Salancik, 2003, p. xxxiii), including joint ventures (Inkpen and Currall, 2004), mergers and acquisitions (Pfeffer, 1972). As a result of cross-industry organizational arrangements (e.g. mergers and acquisitions) between the focal firm and its external organizations (Pfeffer and Nowak, 1976; Pfeffer and Salancik, 2003), corporate unrelated diversification level will, thus, produce an important impact on the focal firm's survival.

Especially under a crisis situation, unrelated diversification level reveals the outcome of the firm's internalization of various external resources from different industries (Pfeffer, 1972; Pfeffer and Salancik, 2003). This determines the corporate dependence level on external resources and its autonomy level in regard to the available resources (Oliver, 1991; Pfeffer and Salancik, 2003). The crisis' outbreak often requires the firm to timely organize its resources to deal with it for reducing the losses of the firm itself and its stakeholders (Bundy and Pfarrer, 2015). Under such situation, unrelated diversification level, as a manifestation of the corporate resource dependence and autonomy level, affects the corporate ability to deal with emergencies, thus affecting its survival (Oliver, 1991; Pfeffer, 1972).

The "onset of a crisis is characterized by high levels of uncertainty about a firm among its stakeholders" (Bundy and Pfarrer, 2015; Wei et al., 2017, p. 2106). Under this uncertainty condition, stakeholders tend to assess the crisis' impacts on the firm by relying on their perceptions of the corporate abilities to solve the crisis (Oliver, 1991). Their responses to the crisis, thus, should be affected by the corporate unrelated diversification level.

2.2 Attribution of knowledge deficiency in crisis

The concept of knowledge, defined as "the awareness of what one knows through study, reasoning, experience or association or through various other types of learning", has received considerable attention in the literature (Del Giudice and Della Peruta, 2016; McInerney, 2002, p. 1009; Santoro et al., 2020; Schoenherr et al., 2014). Corporate knowledge in particular can be seen from different perspectives (Polanyi, 1966; Quinn, 1999). For instance, Quinn (1999) equates corporate knowledge with professional intelligence within an organization, and divided it into four categories, namely, "cognitive knowledge," "advanced skills," "systems understanding" and "self-motivated creativity." Polanyi (1966) divided corporate knowledge more concisely into two types, namely, "explicit knowledge" and "tacit knowledge." The former refers to knowledge that can be systematized, standardized and recorded (McInerney, 2002) such as production technology knowledge. While the latter is indescribable knowledge residing in the human mind such as values and implicit ways of doing things (Polanyi, 1966).

Corporate knowledge has been widely regarded in the past literature as a significant factor in enhancing the firm value in a dynamic business environment (Del Giudice and Maggioni, 2014; Nyuur et al., 2019; Scuotto et al., 2017). From the perspective of explicit knowledge, advanced explicit knowledge (e.g. manufacturing technique) can help firms gain competitive advantages over rivals and thus improve their own value (Schoenherr et al., 2014). Meanwhile, from the perspective of tacit knowledge, excellent tacit knowledge can help firms obtain the wider favor and reward from stakeholders, which has important impacts on the promotion of corporate value (Chin et al., 2019; Nyuur et al., 2019). For instance, corporate social responsibility (CSR) behavior, as the concrete embodiment of firm's good tacit knowledge, can enable firms to obtain the trust from multiple stakeholders such as employees, customers and suppliers (Nyuur et al., 2019). In turn, these stakeholders will reward firms through increased productivity, consumer loyalty and other outcomes that maximize the corporate reputation and competitiveness, and thus enhance corporate value (Nyuur et al., 2019).

Although past literature has focused extensively on the positive role of corporate knowledge in influencing the firm value, with less attention paid to the harm of corporate knowledge deficiency on it. In reality, a higher value obtained by firms based on their superior corporate knowledge may quickly dissipate due to the crises caused by knowledge deficiencies. For instance, in 2016, South Korea's Samsung was abandoned by the Chinese market because of its senior executives' reluctance to recall the faulty phones sold in mainland China at the mobile phone explosion event's onset. Before that, it previously held nearly a third of the market shares in China [2]. Exploring the impact of the corporate knowledge deficiency on firm value under a crisis situation is thus great significant.

Past studies have shown that situational factors play a key role in influencing how stakeholders interpret corporate crises (Bundy and Pfarrer, 2015; Wei et al., 2017). Attribution theory argues that humans are intuitive psychologists who try to comprehend their environment and seek causal explanations, especially when the events are negative and unexpected (Weiner, 2006). At the crisis' onset, stakeholders usually tend to identify its causes based on characteristics such as their perceived intention, controllability and severity (Coombs, 2007). In turn, these causal attributions will affect the stakeholders' perceptions of, and attitudes toward, a firm (Wei et al., 2017). Corporate knowledge deficiency, as an important perceived cause, usually represents a vital identification target when stakeholders try to comprehend the crisis (Coombs, 2004; Laufer and Coombs, 2006). We, thus, speculate that the attribution of knowledge deficiency perceived by stakeholders will affect their responses to the crisis, and thus influence the firm value.

3. Hypothesis development

3.1 Effect of unrelated diversification

Based on the view of RDT, unrelated diversification implies an organizational structure that is constructed by a special interaction between the firm and its external partners that are not in the same industry (Pfeffer and Nowak, 1976; Pfeffer and Salancik, 2003). At the crisis' onset, this structure affects the firm's survival by determining its dependence and autonomy level on resources (Drees and Heugens, 2013; Oliver, 1991). Accordingly, unrelated diversification can influence corporate stakeholders' perceptions and decision-making following a crisis event (Ataullah *et al.*, 2014).

In responding to a corporate crisis, stakeholders rely on information other than the event itself, including the corporate unrelated diversification level, to form their evaluation basis (Ataullah *et al.*, 2014; Godfrey *et al.*, 2009). At the crisis' onset, a firm with higher unrelated diversification level usually possesses a lower dependence level on external resources (Drees and Heugens, 2013), and a higher autonomy level in its internal resources (Oliver, 1991). This condition allows the firm to timely rely on its internal resources to disperse and defuse the crisis' risks, so as to reduces the losses for itself and its stakeholders (Coombs, 2007). Based on this, higher unrelated diversification level may positively affect the stakeholders' assessments of the crisis' impacts on the firm, and thus protect the firm value at the crisis' onset. We thus postulate:

H1. Unrelated diversification has a positive effect on the firm's market value at the crisis' onset.

3.2 Moderating effect of corporate transparency

As a special organizational structure, unrelated diversification reveals firms usually possess a variety of cross-industry knowledge (Hadlock *et al.*, 2001). Although the firm's internal staff may be able to access the classified knowledge about various parts of the diversified firm, outside investors may not have access to the relevant cross-industry knowledge (Thomas, 2002). Additionally, "the interactions among different segments, which are likely to possess distinctive cognitive assets, make diversified firms more complex and harder for outsiders to understand" (Aoki, 2010; Ataullah *et al.*, 2014, p. 230). In this case, the value of unrelated diversification may be underestimated by external stakeholders (Ataullah *et al.*, 2014).

"Transparency the perceived quality of intentionally shared information from a sender" (Schnackenberg and Tomlinson, 2016, p. 1788). About the firm and its stakeholders, "transparency is seen as a critical element of knowledge sharing such that increased transparency brings increased awareness, coherence, and comprehensibility to information exchanged between two parties" (Schnackenberg and Tomlinson, 2016, p. 1788). Accordingly, higher corporate transparency level reduces the information asymmetry between the firm and its stakeholders and breaks the cross-industry knowledge barrier for the stakeholders (Aoki, 2010). This condition helps external stakeholders to perceive the benefits of unrelated diversification to the firm value, especially at the crisis' onset. On the contrary, lower corporate transparency level strengthens the cross-industry knowledge barrier for stakeholders (Aoki, 2010), which makes them unable to comprehensively understand the value of unrelated diversification to the firm (Ataullah *et al.*, 2014). At the crisis' onset, therefore, the stakeholders' response is likely unaffected by the unrelated diversification level. We thus predict:

H2. There is a positive interaction between unrelated diversification and corporate transparency on the firm's market value such that the positive effect of unrelated diversification is stronger when corporate transparency is high (vs low).

3.3 Main and moderating effects of knowledge deficiency attribution

Several attributions of corporate crises exist in the literature (Connelly *et al.*, 2016; Coombs, 2004). For example, Coombs (2004) divides corporate crises into three clusters, i.e. victim, accident and intention, according to the crisis responsibility attributions. Connelly *et al.* (2016) argue that crises are caused by two types of corporate failures, which they label as competency failure and integrity failure. In this study, based on attribution theory (Weiner, 2006), and the classification of corporate knowledge, i.e. explicit and tacit knowledge (Chin *et al.*, 2018; McInerney, 2002), we hold that, with the exception of the crises in which the firms are perceived as victims, firms' crises are caused by their explicit and tacit knowledge deficiencies (Laufer and Coombs, 2006; Papa *et al.*, 2018; Wang Chun-hsien *et al.*, 2020). We, thus, divide the crises into three clusters, namely, victim, explicit knowledge and tacit knowledge.

The victim cluster includes crises that are perceived as having no knowledge deficiency, with the firm perceived as a crisis' victim (Coombs, 2007). Examples of this kind of crises include product tampering and rumors (Coombs, 2004). The explicit knowledge cluster includes crises caused by corporate explicit knowledge deficiency such as technical failure incidents (Laufer and Coombs, 2006). As explicit knowledge has attributes that can be documented and modified (Santoro *et al.*, 2019), this deficiency is perceived as having lower difficulty level of repair, with the crisis seen as unintentional and solvable (McInerney, 2002). Finally, tacit knowledge cluster includes crises caused by corporate tacit knowledge deficiency such as financial fraud events (Staubus, 2005). Due to the incalculable and unpredictable characteristics of tacit knowledge (Chin *et al.*, 2019; McInerney, 2002), this deficiency is perceived as having higher difficulty level of repair (Connelly *et al.*, 2016), with the crisis seen as intentional and unmanageable (Santoro *et al.*, 2019).

Stakeholders often attribute the crisis' cause to corporate knowledge deficiency (Coombs, 2007; Ferreira et al., 2018) and their attributions may influence their attitudes toward the firm (Wei et al., 2017). The corporate knowledge deficiency perceived by stakeholders as more difficult to be repaired, the less trust they have in the firm because the deficiency is more likely to pose a long-term threat to the interests of the firm and its stakeholders (Bundy and Pfarrer, 2015; Connelly et al., 2016). In consequence, they may punish the firm depending partly on their knowledge deficiency attributions. We thus hold that the shareholders' responses to the crisis may become more severe as perceived difficulty level of repairing the knowledge deficiency increases, as the crisis cluster changes from victim, to explicit knowledge and to tacit knowledge. We thus predict:

H3. The negative effect of corporate crises on the firm's market value is stronger as the knowledge deficiency attribution increases.

As we argued earlier, the buffering effect of unrelated diversification should alleviate the damage of a crisis to the firm value – as a result of the stakeholders' tendency to evaluate the crisis' impacts on the firm by their perceptions of the corporate ability to solve emergencies. This is especially likely to happen when there is no or limited difficulty level of repairing the knowledge deficiency (i.e. victim or explicit knowledge deficiency cluster), which would make stakeholders trust that the firm can rely on its own resources to solve the crisis autonomously. This effect should be weakened, however, when the knowledge deficiency is attributed to the tacit knowledge deficiency. Under this condition, stakeholders find it hard to believe that firms can repair knowledge deficiency through its own efforts. Just as the devil effect's viewpoint (Bradburn *et al.*, 2004), "a single dishonest behavior is sufficient to produce a confident attribution that the actor is dishonest" (Reeder and Brewer, 1979, p. 68). In consequence, the firm value should be significantly and consistently depressed when the crisis' cause is attributed to the tacit knowledge deficiency, regardless of what the corporate unrelated diversification level is. We thus predict:

H4. There is a negative interaction between unrelated diversification and knowledge deficiency attribution on the firm's market value such that the positive effect of unrelated diversification is stronger when the perceived difficulty level of repairing knowledge deficiency is low (vs high).

4. Methods

4.1 Sample and data sources

We use a sample of crises events related to Chinese listed companies to test our hypotheses. The reason why we examine listed companies is because they are subjected to strict requirements of China's economic regulations for information disclosure such as corporate announcements. Furthermore, their financial statements are widely available (Zavyalova et al., 2012). Following the procedures outlined by Wei et al. (2017), we investigate crisis events by reviewing news reports in China Business News and the China Securities Journal published between 2008 and 2018. China Business News is a major newspaper for business and economic news whose reports are timely and accurate, while the China Securities Journal is a significant international newspaper, which provides information about Chinese listed firms. There were 233 crises during the study period. We removed 30 observations, which were confounded by releases of information about significant events, for example, announcement of major sales or mergers within seven days of a crisis (Godfrey et al., 2009). The final sample consists of 203 crisis events. Detailed information about the crises and firms is shown in Appendix Tables A1 and A2.

4.2 Dependent variable: cumulative abnormal returns

The dependent variable in the regression models used to investigate the potential influence of a crisis event on corporate market value is cumulative abnormal adjusted returns (CAR). A firm's CAR connected with a crisis event is calculated over a three-day (-1, 1) time window. This is in line with previous studies arguing that this method can timely "capture possible information leakage prior to a crisis while minimizing confounds of post-crisis events" (Wei *et al.*, 2017, p. 2109). The calculation method of CAR is as follows.

Abnormal returns refer to the unexpected percentage-gaps between the expected normal return and the real return. Following prior research (Godfrey *et al.*, 2009; Wei *et al.*, 2017), the market model is applied to obtain the expected normal return, abnormal return and cumulative abnormal returns, namely:

$$Rit = Ai + BiRmt + Eit$$
,

where R_{it} represents the normal return of security i on day t, Ait captures the intercept and B_i is the systematic risk associated with security I; Rmt is the return on the market portfolio of stocks on day t and E_{it} is the error term of security i on day t. Subsequently, the abnormal return is estimated as:

$$ARit = Rit - (Ai + BiRmt).$$

In this model, AR_{it} represents the abnormal return of security i on day t and A_i and B_i are the ordinary least squares parameter estimates of security i. Thus, the three-day cumulative abnormal return (CAR_{3-day}) over the 3-day (n: -1, 0, +1) event window for each security i is calculated as follows:

$$CAR_{3-day} = \sum_{t=n}^{n=(-1,0,+1)} ARit$$

The expected returns are calculated for the period of 128 to 8 trading days before the critical incident (i.e. a total of 120 trading days) (Wei et al., 2017). Furthermore, the daily

market return volatility is calculated using the equal weight average of the Shanghai stock exchange composite index and the Shenzhen stock exchange component index. All return and market data were obtained from the Accounting Research Database (CSMAR, www.gtarsc.com/Home).

4.3 Independent variables

4.3.1 Unrelated diversification. We analysis the corporate unrelated diversification level because it exposes firms to more situations where the information and agency effects can be manifested. On the one hand, unrelated diversification level reveals the knowledge convergence of different industries present in each firm, which may trigger the "information effect." On the other hand, the "agency effect" of unrelated diversification may be of more concern to stakeholders because cross-industry operations provide managers with greater opportunities to reduce the risk of their own interests being damaged (Ataullah et al., 2014).

Each firm's unrelated diversification level is measured by the method of entropy. According to this method, the unrelated diversification level reveals the amount of company sales derived from different two-digit Standard Industrial Classification (SIC) industry groups [3]. All data are available from the CSMAR. The unrelated diversification (UD) is calculated as:

$$UD = \sum_{j=1}^{n} Pj \log(1/Pj)$$

where P_j is the proportion of the j-th industry group sales in the corporate total sales. Larger values for the entropy measure reveal less concentration of sales within industry groups and represent higher unrelated diversification level.

4.3.2 Attribution of knowledge deficiency. To measure the attribution of knowledge deficiency, we reviewed news coverage of each crisis at its onset. Two of the authors used the coding scheme of Schoenherr et al. (2014), Wei et al. (2017) and Connelly et al. (2016) to separately code each crisis based on its descriptions, and categorized all crises into different types, including "product harms, product defects, product tampering, malicious rumors, technical accidents, organizational misdeed, environment spill, stealth pollution and financial fraud" (Wei et al., 2017, p. 2111) (Appendix Table A1). All codes were 95% consistent between the two coders, manifesting high reliability (Weber, 1990). The remaining 5% difference was resolved through discussions to reach consensus. Finally, to test the coding's veracity, we also invited a visiting scholar to code 50 randomly selected critical events and the results were still reliable with a compliance rate of 89%. The different types of crises were then classified into three clusters, including "victim" (coded as 1), "explicit knowledge" (coded as 2) and "tacit knowledge" (coded as 3). For instance, if at the crisis' onset, the news coverage describes no quality problem at the firm itself but at other pharmaceutical firms, the event can be regarded as the type of product harms, and the firm can be classified as the victim (Wei et al., 2017). If the news coverage describes a factory explosion caused by employees' technical problem, the event can be regarded as the technical accidents type that belongs to the explicit knowledge deficiency (Schoenherr et al., 2014). Finally, if the news coverage describes a financial fraud incident caused by a joint fraud of the company's general manager and chief financial officer, the event can be regarded as the financial fraud type that belongs to the tacit knowledge deficiency (Schoenherr et al., 2014; Connelly et al., 2016). The higher the score, the higher the perceived difficulty level of repairing the knowledge deficiency.

4.4 Moderating variable: corporate transparency

Following Xu et al. (2019), we define corporate transparency as the number of announcements a firm makes in the year prior to a crisis. The data about the number of

announcements come from the well-known financial terminal Choice (http://choice.eastmoney.com/), which is an Internet Big Data Financial Hyper Terminal for different users such as financial investment institutions, research and academic organizations (Xu et al., 2019). Most importantly, this database can timely update corporate announcements, financial and operational data and research reports.

4.5 Control variables

We controlled for the following factors to ensure the results are robust. For corporate characteristics, to explain the possibility that large firms may attract more attention from stakeholders (Zavyalova et al., 2012), the log-transformed values of annual sales before the crisis were used to measure the firm size. We also controlled for Tobin's Q, profitability and leverage in the year before the crisis, which are known to correlate with the firm's market value (Wei et al., 2017). Profitability was measured by the ratio of the net profit margin on sales and leverage was measured by the asset-liability ratio. These data were obtained from the CSMAR.


For event attributes, considering the influence of the *type of crisis* on the attribution, we also created and controlled three dummies for the crisis types that occurred most frequently in our data, including technical accidents (19%), organizational misdeed (19%) and product harms (11%). The *number of fatalities* in a crisis always determines its social influence level, we thus controlled for this variable (Lo *et al.*, 2018). Considering the potential effects of industry attributes, we further controlled for *return on assets* of corporate main business industry in the year before the crisis (Chang and Thomas, 1989) and measured it by the ratio of industry net profit to total industry assets. Finally, to exclude the potential effects of corporate market competitive advantage on stakeholders' responses to the firm, we also controlled for the *market share* in the corporate main business industry, which was measured by the proportion of corporate main business revenue and industry revenue in the year before the crisis (Chang and Singh, 2000). These data were obtained from CSMAR and the Choice database.


5. Results

The daily average abnormal returns (AAR) are shown in Figure 1 where negative values indicate that the crisis events have a negative impact on the firm value. Abnormal returns are significantly depressed on the day of the crisis as well as over the two-day period following the crisis event (i.e. day 0 to day 2). The vulnerability was significantly high for the two days before a crisis (i.e. day -1 and day -2), indicating possible crisis information leakage that induces an earlier negative reaction among stakeholders (Wei *et al.*, 2017). All descriptive data for the variables are presented in Table 1.

Table 2 includes the regression models showing the values of CAR connected with crises in the 3-day window (i.e. day [-1, 1]). We estimated Model 1 as the base model, which includes only control variables. The main effects of independent variables, i.e. unrelated diversification and attribution of knowledge deficiency and moderating variable, i.e. corporate transparency, are added in Model 2. Additionally, we respectively included the moderating effect of corporate transparency on unrelated diversification in Model 3 and the interaction effect of unrelated diversification and attribution of knowledge deficiency in Model 4. Model 5 is the full model that contains all main and moderating effects in this study. The highest variance inflation factor (VIF) in Model 5 is 1.640. Multicollinearity is, thus, not a serious problem in our data.

Model 2 tests the main effects of unrelated diversification and attribution of knowledge deficiency. The increase in the R^2 statistic from Model 1 to Model 2 is significant (0.060, p = 0.000). Unrelated diversification is significantly and positively related to CAR (p = 0.011), supporting H1 that unrelated diversification can provide a buffering effect for the firm value





at the crisis' onset. This buffering effect is also seen as the benefits associated with unrelated diversification in this study. Additionally, the attribution of knowledge deficiency has a negative and significant effect on CAR (p = 0.007), supporting H3 that stronger attribution of knowledge deficiency represents a burden for investors at the crisis' onset.

The moderating effect of corporate transparency on unrelated diversification is tested by Model 3. The increase in the R^2 statistic from Models 2 to 3 is significant (0.045, p=0.000). A positive and significant moderating effect of corporate transparency on unrelated diversification (0.237, p=0.001) is revealed. The positive effect of unrelated diversification on CAR remains significant at a high-level corporate transparency, but is non-significant at a low-level of corporate transparency. H2 is thus supported. For further interpreting this moderating effect, based on the Johnson–Neyman technique (Hayes, 2017; Spiller *et al.*, 2013), we identified the region indicating the range of corporate transparency beyond which the effect of unrelated diversification is significant (Figures 2 and 3). According to the figures, only when the value of the corporate transparency is greater than 79 can the positive effect of unrelated diversification be significant.

Model 4 tests hypothesis 4 by examining the interaction between unrelated diversification and attribution of knowledge deficiency. The R^2 statistic increases significantly from Models 2 to 4 (0.034, p=0.000). A negative interaction effect between unrelated diversification and attribution of knowledge deficiency is revealed by the regression analysis (-0.201, p=0.005). The analysis shows that the unrelated diversification has a positive effect on the abnormal stock return for the victim (0.576, p=0.003) and explicit knowledge deficiency (0.203, p=0.018), but its effect is negative and not significant for the tacit knowledge deficiency (-0.002, p=0.990) (Figure 4). That is, unrelated diversification buffers the negative effect of crises on investor reaction only when the initial attribution of knowledge deficiency is at a lower level (i.e. victim and explicit knowledge deficiency), but not when it is higher (i.e. tacit knowledge deficiency). This depression of the firm value condoned by the unrelated diversification is regarded as the costs associated with unrelated diversification. These results are supportive of H4. We also tested all above results by adding all main and moderating effects simultaneously, the results still remained substantially unchanged (see Model 5).

Among the control variables, severe crises that result in a great number of fatalities damage more the firm value. A positive and significant effect of the corporate market share on CAR

1. CAR ³	-0.020	0.056						
2. CAR ⁷	-0.026	0.079	0.811** (0.000)					
3. Profitability	0.094	0.153	-0.176*(0.012)	-0.126(0.072)				
4. Tobin Q	2.901	1.975	-0.071(0.312)	-0.115*(0.103)	0.255** (0.000)			
5. Leverage	0.477	0.208	$0.119^{**}(0.090)$	0.198**(0.005)	-0.223^{**} (0.000)	-0.385** (0.000)		
6. Firm size	9.550	0.648	0.078(0.269)	0.071(0.315)	0.010(0.891)	-0.176*(0.012)	0.259**(0.000)	
7.Number of fatalities	2.281	10.567	-0.181**(0.010)	-0.234^{**} (0.001)	0.103(0.143)	-0.066(0.350)	-0.091(0.197)	0.137(0.051)
8. Product harms	0.108	0.312	-0.103(0.143)	-0.071(0.317)	0.008(0.143)	0.002 (0.980)	-0.095(0.179)	(866.0) 000.0
9. Technical accidents	0.191	0.395	0.022 (0.758)	0.094 (0.184)	-0.024(0.729)	-0.128 (0.068)	0.127(0.071)	0.078(0.271)
10. Organizational misdeeds	0.182	0.387	0.019 (0.792)	0.017 (0.811)	(666.0)000.0	0.167*(0.018)	0.103 (0.143)	-0.083(0.237)
11. Return on industry assets	0.058	0.034	-0.153*(0.030)	-0.121(0.085)	0.221** (0.002)	0.299**(0.000)	-0.366*(0.000)	-0.051(0.471)
12. Market share	4.147	7.555	0.145*(0.039)	0.094 (0.182)	0.138*(0.050)	-0.051(0.473)	0.200**(0.004)	0.541** (0.000)
13. Corporate transparency	0.984	0.497	-0.025(0.724)	-0.054(0.442)	-0.020(0.775)	0.090(0.201)	-0.023(0.743)	-0.045(0.526)
14. Unrelated diversification	0.290	0.332	0.172^{*} (0.014)	0.153*(0.029)	-0.151*(0.031)	-0.084(0.232)	0.234** (0.001)	-0.015(0.834)
15. Attribution of knowledge deficiency	2.251	0.711	-0.152*(0.030)	-0.171*(0.015)	-0.040(0.575)	0.025 (0.718)	0.041 (0.560)	-0.031 (0.658)
Notes: $n = 203$; p -value are in parentheses	Se							
								(continued)


 Table 1
 Descriptive statistics and bivariate correlations

0.013 (0.849)

Variables	Model 1	p-value	Model 2	p-value	Model 3	p-value	Model 4	p <i>-value</i>	Model 5	p-value
(Constant)	0.017 (0.095)	0.861	-0.042 (0.094)	0.659	-0.036 (0.092)	0.694	-0.026 (0.093)	0.776	-0.022 (0.090)	0.812
Profitability	-0.165(0.073)	0.025	-0.167 (0.071)	0.020	-0.152(0.069)	0.030	-0.165(0.070)	0.019	-0.150(0.068)	0.029
Tobin's Q	-0.006(0.079)	0.936	-0.015(0.077)	0.848	-0.036(0.075)	0.636	-0.028(0.076)	0.717	-0.048(0.074)	0.522
Leverage	-0.031(0.083)	0.703	-0.087(0.082)	0.290	-0.135(0.082)	0.101	-0.109(0.081)	0.180	-0.155(0.081)	0.056
Firm size	-0.009(0.084)	0.918	-0.038(0.082)	0.646	-0.029(0.080)	0.714	-0.037(0.080)	0.642	-0.029(0.078)	0.709
Number of fatalities	-0.200(0.072)	900.0	-0.161(0.071)	0.024	-0.169(0.069)	0.015	-0.175(0.070)	0.013	-0.182(0.068)	0.008
Product harm	-0.367(0.231)	0.113	-0.236(0.230)	0.307	-0.247(0.224)	0.272	-0.268(0.226)	0.237	-0.278(0.221)	0.209
Technical accidents	0.142 (0.188)	0.452	0.101 (0.184)	0.583	0.156 (0.180)	0.387	0.092(0.180)	0.612	0.146 (0.177)	0.410
Organizational misdeed	-0.023(0.191)	906.0	0.262 (0.208)	0.209	0.179 (0.204)	0.382	0.223 (0.205)	0.279	0.143 (0.201)	0.479
Return on industry assets	-0.101(0.076)	0.187	-0.124(0.076)	0.108	-0.144(0.075)	0.055	-0.128(0.075)	0.091	-0.148(0.073)	0.046
Market share	0.208(0.084)	0.014	0.281 (0.084)	0.001	0.292 (0.082)	0.000	0.283(0.083)	0.001	0.293(0.081)	0.000
Corporate transparency (CT)			-0.053(0.069)	0.439	-0.065(0.067)	0.339	-0.079(0.068)	0.249	-0.089(0.067)	0.184
Unrelated diversification (UD)			0.181 (0.071)	0.011	0.246(0.072)	0.001	0.177 (0.069)	0.012	0.240 (0.070)	0.001
Attribution of knowledge deficiency (AD)			-0.207(0.076)	0.007	-0.154(0.076)	0.045	-0.215(0.075)	0.005	-0.163(0.075)	0.031
UD*CT					0.237 (0.072)	0.001			0.231(0.071)	0.001
UD*AD							-0.201(0.071)	0.005	-0.195(0.070)	0.006
H2	0.120		0.180		0.225		0.214		0.256	
R^2 adj	0.074		0.124		0.167		0.155		0.196	
F-statistic	2.615**		3.201**		3.897**		3.650**		4.291**	



Conditional effect of unrelated diversification on crisis-CAR as a function of corporate transparency



Notes: Following the Johnson–Neyman technique, the two dashed curves represent the boundary of 95% confidence interval (95% CI upper limit and 95% CI lower limit). The solid line in the middle reveals the point estimate of conditional effect of unrelated diversification. The vertical dashed line represents the critical point (i.e. 79) of moderating effect of corporate transparency on the positive effect of unrelated diversification on Crisis-CAR. The horizontal dashed line represents the critical point (i.e. 0) of the positive effect of unrelated diversification on crisis-CAR. They both dashed lines intersect at the dashed curve of 95% CI lower limit and reveals that the positive effect of unrelated diversification on crisis-CAR will be strengthened when the value of corporate transparency high than 79


was also tested, suggesting that higher competitive advantage in the market could result in the firms suffering less damage at the crisis' onset.

6. Robustness checks

A series of robustness checks were performed to further confirm the results from this study. First, we calculated the seven-day CAR and ran the models again. The main results did not change (Appendix Table A3). Second, considering the high correlation between the crisis types and attribution of knowledge deficiency, we also conducted a robustness check by analyzing the models without the three dummy variables. Our results did not change (Appendix Table A4).


Third, we selected substitution variables to measure unrelated diversification and corporate transparency again. For unrelated diversification, we chose the measurement of the Blau coefficient (Blau, 2001) to replace the method of entropy measure [4]. The results also did not change (Appendix Table A5). For corporate transparency, we respectively chose the number of announcements made by the firms in the two (and three) years before the crisis to replace the number of announcements in the one year prior to the crisis. We reran the regression model and the results did not change (Appendix Tables A6 and A7).

Figure 3 Moderating effect of corporate transparency on unrelated diversification



Notes: The two solid lines represent the lowest (=23) and highest (=246) levels of corporate transparency. The middle dashed line represents the switching point of corporate transparency (=79) below which the effect of unrelated diversification is positive and significant (p<0.05) but above which the effect of unrelated diversification is not significant (p>0.1). This is done using the Johnson–Neyman technique. The shaded area thus represents the Johnson–Neyman region of significance

Figure 4 Interaction effect of unrelated diversification and attribution of knowledge deficiency on crisis-CAR



Finally, for additional control variables, we also considered the effects of corporate tenure in the stock market and type. The former was measured by the time interval between the date when the firm went public and the date of the event. For the latter, we created four dummies for the corporate types that occurred most frequently in our data, including pharmacy (30.5%, 62), manufacturing of chemical materials and products (8.3%, 17), wine, beverage and refined tea manufacturing (6.4%, 13) and capital market services (0.9%, 2). After re-running the regression model by adding them as control variables, all results did not change (Appendix Tables A8 and A9). All robustness checks confirmed the vigor of our findings.

7. Discussion, conclusion and limitations

7.1 Discussion

Although past research has extensively explored the effects of diversification strategy on the firm value in daily operations (Aggarwal and Samwick, 2003; Ataullah *et al.*, 2014; Chen and Keung, 2018), there is insufficient analysis of its impacts in a crisis situation. Using an event study of 203 corporate crises in China, we tested the relationships between the unrelated diversification, corporate transparency, knowledge deficiency attribution and the stock market's responses to the crisis. Our empirical results show that in a crisis situation the "information effect" and "agency effect" of unrelated diversification on the firm value can be partially explained.

Using a cross-border knowledge management perspective (Aoki, 2010; Hadlock *et al.*, 2001), we explored a unique dimension of corporate diversification – unrelated diversification, which captures the external stakeholders' perception of corporate cross-industry knowledge (Chen and Keung, 2018). Our investigation of the interaction between unrelated diversification and corporate transparency shows that firms with higher unrelated diversification level are initially insulated from crises, especially when they possess higher transparency. These results resonate with the conclusion of Ataullah *et al.* (2014) that corporate transparency plays a crucial role in the external stakeholders' correct assessment of unrelated diversification value, revealing the "information effect" of diversification in a crisis situation. In this case, the benefits associated with unrelated diversification can be thus obtained by the firm.

The simultaneous examination of unrelated diversification and corporate transparency also allowed us to illuminate the effect of centralized strategy on the firm value at the crisis' onset. Figure 3 reveals, at very low unrelated diversification levels (i.e. centralized strategy), the firm value drop significantly when corporate transparency is higher. This phenomenon may reveal the fact that high daily interaction between the firm and stakeholders makes the stakeholders more aware of the limitations in the abilities of centralized firms to spread the crises' risk. Additionally, these results could also be combined with the Kang's (2013) research, which explores the impacts of unrelated diversification on the firm's willingness to communicate with its stakeholders, to further explore the reasonable information disclosure mechanism of firms in response to crises.

Additionally, our finding that perceived corporate knowledge deficiency in the crisis has effects on the firm value provides empirical evidence for the impacts of causal attribution which was hypothesized but rarely tested previously (Coombs, 2004). Meanwhile, our results also show that the buffering effect of unrelated diversification is valid only when the crisis' cause is not attributed to the tacit knowledge deficiency by stakeholders. These results could partly explain the "agency effect" of diversification in a crisis situation (Aggarwal and Samwick, 2003), that is, unrelated diversification will not have the positive impact on the firm value at the crisis' onset if the corporate managers are perceived as having ethical deficiency. In this case, the costs associated with unrelated diversification will be suffered by the firm.

7.2 Implications and conclusion

7.2.1 Theoretical contributions. Firs, prior literature has extensively discussed the influence mechanism of diversification on the firm value in daily operations (e.g. "information effect" and "agency effect" of diversification) (Ataullah et al., 2014; Denis et al., 1999). In this study, based on the stakeholders' responses to the corporate crisis in the context of information asymmetry (Bundy and Pfarrer, 2015; Wei et al., 2017), we partly explain the agency and information effects of diversification with cross-industry knowledge in a crisis situation. These findings expand the research perspective of cross-industry knowledge management to the crisis management field and shed new light on the long-standing discussion of the value of diversification strategy to the firm in the strategic management literature.

Second, in the literature on applied attribution theory, responsibility attribution has long been regarded as a critical construct in determining stakeholders' response to corporate crises (Bundy and Pfarrer, 2015). However, one point that is usually neglected previously is that at the crisis' onset, stakeholders should attribute the crisis' cause first and then make the responsibility attribution. For instance, before the firm takes more responsibility for the crisis such as financial fraud, stakeholders should have attributed the crisis' cause to corporate ethical failings rather than competence problems or rumor. We, therefore, extend the application of attribution theory by empirically testing the influence of knowledge deficiency attribution on the firm value at the crisis' onset.

Finally, prior literature based on resource dependence view held that the key to protecting the firm value is to reduce its dependence on external resources (Oliver, 1991; Pfeffer and Salancik, 2003) while those based on agency theory emphasized that effective supervision of managers is an effective way to reduce agency cost and thus improve corporate performance (Hillman and Dalziel, 2003; Jensen and Meckling, 1979). Although these two fields have been intensively studied previously, only a few studies have focused on the interaction between these two modes of firm value intervention. By empirically testing the interaction between attribution of knowledge deficiency and unrelated diversification under a crisis scenario, we find that when the supervision mode fails (e.g. firms are considered to possess tacit knowledge deficiency), the protection mode will be also invalid (i.e. the buffering effect of unrelated diversification is ineffective). These findings thus provide meaningful insights into the jointly discussion of the two theories.

7.2.2 Practical implications. First, the exploration of the buffering effect of unrelated diversification in a crisis situation assists firms to understand the stakeholders' crisis response mechanism – stakeholders tend to rely on their perceptions of the firm's unrelated diversification level to evaluate the impacts of crises to the firm and then response to the crises, so as to help firms to repair the crisis-caused damage by making better use of their own strategic advantages. For instance, after the crisis, unrelated diversified firms can promote the initial positive evaluation of stakeholders by quickly publicizing their advantages in the autonomy of diversified resources, so as to mitigate the damage of the crisis to the firm value.

Second, the finding of the information effect of unrelated diversification in a crisis scenario suggests that firms with unrelated diversification structure should increase their daily information interaction with stakeholders, so as to increase stakeholders' understanding of the benefits of unrelated diversification strategy to the firm value. Also, firms implementing centralized strategy should avoid causing concern to stakeholders about their ability for resource autonomy while communicating with them.

Finally, the partly explanation of the agency effect of unrelated diversification in a crisis scenario suggests that at the crisis' onset, firms need try to avoid creating stakeholders' perceptions that the crisis is caused by corporate tacit knowledge deficiency. If the firms fail, the corporate crisis repair behaviors should focus on eliminating the negative cognitive

bias of stakeholders toward the firms. One possible solution is to replace the CEO and all employees involved in the crisis.

7.2.3 Conclusion. In studying how corporate diversification with cross-industry knowledge affects stakeholders' reactions to a corporate crisis, we provided empirical evidence for the combined effects of corporate unrelated diversification, corporate transparency and attribution of knowledge deficiency on the corporate market value at the crisis' onset. Our research extends the "agency effect" and "information effect" of diversification on the firm value in a crisis scenario, and enlightens how firms can better conduct corporate strategic and knowledge management in their daily operations to better cope with crises in the future.

7.3 Limitations and future work

Several limitations of this study provide more opportunities for future research. First, based on the perspective of cross-border knowledge management, this study only explored the impact of unrelated diversification on the firm value in the context of a crisis. Future research can further explore the effects of related diversification on the stakeholders' crisis responses, and discuss the differential effects of these two dimensions of diversification strategies in a crisis situation.

Second, in this study, we focused on how unrelated diversification, corporate transparency and attribution of knowledge deficiency jointly affect the firm value at the crisis' onset. After the crisis' initial stage, different intermediaries such as news media, We-Media and even the firms themselves, often provide investors with more crisis-related information (Bundy and Pfarrer, 2015). Therefore, with the development of the crisis, how these independent variables in this study interact with other factors to jointly influence the firm value deserves further systematic investigation in the future.

Finally, although this study has controlled for many variables related to the firm, crisis and industry, other variables may also drive the relationship between unrelated diversification and the firm value, which is worth further exploration in the future. For instance, future research could explore the corporate crisis experience and how it affects the firm value (Wei et al., 2017). We speculate that whether a firm has had similar crises in the past may have an effect on stakeholders' perceptions of the firm at the crisis' onset.

Notes

- 1. Jensen and Meckling (1979) classify agency costs into monitoring costs, compliance costs and residual costs. Monitoring costs refer to the expenditures of external shareholders to supervise the manager's excessive consumption or self-relaxation; compliance costs mean the self-restraint expenses incurred by managers to gain the external shareholders' trust such as regular financial reporting; other losses due to inconsistent interests of shareholders and managers are residual costs.
- 2. https://www.sohu.com/a/345202947 239259
- 3. http://www.stats.gov.cn/tjsj/tjbz/201905/t20190522_1666232.html
- 4. Blau coefficient: $UD = 1 \sum_{i=1}^{m} P_i j^2$

where Pj is the proportion of the j-th industry group sales in the corporate total sales. The larger values for the Blau coefficient reveal a less concentration of sales among industry groups and represent a higher unrelated diversification level.

References

Aggarwal, R.K. and Samwick, A.A. (2003), "Why do managers diversify their firms? Agency reconsidered", *The Journal of Finance*, Vol. 58 No. 1, pp. 71-118.

Aoki, M. (2010), Corporations in Evolving Diversity: Cognition, Governance, and Institutions, Oxford University Press.

Ataullah, A., Davidson, I., Le, H. and Wood, G. (2014), "Corporate diversification, information asymmetry and insider trading", *British Journal of Management*, Vol. 25 No. 2, pp. 228-251.

Berger, P.G. and Ofek, E. (1995), "Diversification's effect on firm value", *Journal of Financial Economics*, Vol. 37 No. 1, pp. 39-65.

Blau, P.J. (2001), "The significance and use of the friction coefficient", *Tribology International*, Vol. 34 No. 9, pp. 585-591.

Bradburn, N., Sudman, S. and Thorndike, E. (2004), "A constant error on psychological rating", *Journal of Applied Psychology*, Vol. 4 No. 1, pp. 25-29.

Bundy, J. and Pfarrer, M.D. (2015), "A burden of responsibility: the role of social approval at the onset of a crisis", *Academy of Management Review*, Vol. 40 No. 3, pp. 345-369.

Chang, S.-J. and Singh, H. (2000), "Corporate and industry effects on business unit competitive position", *Strategic Management Journal*, Vol. 21 No. 7, pp. 739-752.

Chang, Y. and Thomas, H. (1989), "The impact of diversification strategy on risk-return performance", *Strategic Management Journal*, Vol. 10 No. 3, pp. 271-284.

Chen, G.-Z. and Keung, E.C. (2018), "Corporate diversification, institutional investors and internal control quality", *Accounting & Finance*, Vol. 58 No. 3, pp. 751-786.

Chin, T., Jiao, H. and Jawahar, I. (2019), "Sustainable career and innovation during manufacturing transformation", *Career Development International*, Vol. 24 No. 5, pp. 397-403.

Chin, T., Li, G., Jiao, H., Addo, F. and Jawahar, I. (2019), "Career sustainability during manufacturing innovation", *Career Development International*, Vol. 24 No. 6, pp. 509-528.

Chin, T., Rowley, C., Redding, G. and Wang, S. (2018), "Chinese strategic thinking on competitive conflict: insights from Yin-Yang harmony cognition", *International Journal of Conflict Management*, Vol. 29 No. 5, pp. 683-704.

Chun-Hsien, W., Tachia, C. and Jie-Heng, L. (2020), "Openness and firm innovation performance: the moderating effect of ambidextrous knowledge search strategy", *Journal of Knowledge Management*, Vol. 24 No. 2, pp. 301-323.

Connelly, B.L., Ketchen, D.J., Jr, Gangloff, K.A. and Shook, C.L. (2016), "Investor perceptions of CEO successor selection in the wake of integrity and competence failures: a policy capturing study", *Strategic Management Journal*, Vol. 37 No. 10, pp. 2135-2151.

Coombs, W.T. (2004), "Impact of past crises on current crisis communication: insights from situational crisis communication theory", *Journal of Business Communication*), Vol. 41 No. 3, pp. 265-289.

Coombs, W.T. (2007), "Protecting organization reputations during a crisis: the development and application of situational crisis communication theory", *Corporate Reputation Review*, Vol. 10 No. 3, pp. 163-176.

Davis, J.H., Schoorman, F.D. and Donaldson, L. (1997), "Toward a stewardship theory of management", *Academy of Management Review*, Vol. 22 No. 1, pp. 20-47.

Del Giudice, M. and Della Peruta, M.R. (2016), "The impact of IT-based knowledge management systems on internal venturing and innovation: a structural equation modeling approach to corporate performance", *Journal of Knowledge Management*, Vol. 20 No. 3, pp. 484-498.

Del Giudice, M. and Maggioni, V. (2014), "Managerial practices and operative directions of knowledge management within inter-firm networks: a global view", *Journal of Knowledge Management*, Vol. 18 No. 5, pp. 841-846.

Denis, D.J., Denis, D.K. and Sarin, A. (1999), "Agency theory and the influence of equity ownership structure on corporate diversification strategies", *Strategic Management Journal*, Vol. 20 No. 11, pp. 1071-1076.

Drees, J.M. and Heugens, P.P. (2013), "Synthesizing and extending resource dependence theory: a Meta-analysis", *Journal of Management*, Vol. 39 No. 6, pp. 1666-1698.

Ferreira, J., Mueller, J. and Papa, A. (2018), "Strategic knowledge management: theory, practice and future challenges", *Journal of Knowledge Management*, Vol. 24 No. 2.

Godfrey, P.C., Merrill, C.B. and Hansen, J.M. (2009), "The relationship between corporate social responsibility and shareholder value: an empirical test of the risk management hypothesis", *Strategic Management Journal*, Vol. 30 No. 4, pp. 425-445.

Grant, R.M. and Jammine, A.P. (1988), "Performance differences between the Wrigley/Rumelt strategic categories", *Strategic Management Journal*, Vol. 9 No. 4, pp. 333-346.

Hadlock, C.J., Ryngaert, M. and Thomas, S. (2001), "Corporate structure and equity offerings: are there benefits to diversification?", *The Journal of Business*, Vol. 74 No. 4, pp. 613-635.

Hayes, A.F. (2017), Introduction to Mediation, Moderation, and Conditional Process Analysis: A Regression-Based Approach, Guilford publications.

Hillman, A.J. and Dalziel, T. (2003), "Boards of directors and firm performance: integrating agency and resource dependence perspectives", *Academy of Management Review*, Vol. 28 No. 3, pp. 383-396.

Inkpen, A.C. and Currall, S.C. (2004), "The coevolution of trust, control, and learning in joint ventures", *Organization Science*, Vol. 15 No. 5, pp. 586-599.

Jacquemin, A.P. and Berry, C.H. (1979), "Entropy measure of diversification and corporate growth", *The Journal of Industrial Economics*, Vol. 27 No. 4, pp. 359-369.

Jensen, M.C. and Meckling, W.H. (1979), "Theory of the firm: managerial behavior, agency costs, and ownership structure", *Economics Social Institutions*, Springer, pp. 163-231.

Kang, J. (2013), "The relationship between corporate diversification and corporate social performance", *Strategic Management Journal*, Vol. 34 No. 1, pp. 94-109.

Laufer, D. and Coombs, W.T. (2006), "How should a company respond to a product harm crisis? The role of corporate reputation and consumer-based cues", *Business Horizons*, Vol. 49 No. 5, pp. 379-385.

Lo, C.K., Tang, C.S., Zhou, Y., Yeung, A.C. and Fan, D. (2018), "Environmental incidents and the market value of firms: an empirical investigation in the Chinese context", *Manufacturing & Service Operations Management*, Vol. 20 No. 3, pp. 422-439.

McInerney, C. (2002), "Knowledge management and the dynamic nature of knowledge", *Journal of the American Society for Information Science and Technology*, Vol. 53 No. 12, pp. 1009-1018.

Nyuur, R.B., Ofori, D.F. and Amponsah, M.M. (2019), "Corporate social responsibility and competitive advantage: a developing country perspective", *Thunderbird International Business Review*, Vol. 61 No. 4, pp. 551-564.

Oliver, C. (1991), "Network relations and loss of organizational autonomy", *Human Relations*, Vol. 44 No. 9, pp. 943-961.

Papa, A., Dezi, L., Gregori, G.L., Mueller, J. and Miglietta, N. (2018), "Improving innovation performance through knowledge acquisition: the moderating role of employee retention and human resource management practices", *Journal of Knowledge Management*, Vol. 24 No. 3.

Pfeffer, J. (1972), "Merger as a response to organizational interdependence", *Administrative Science Quarterly*, Vol. 17 No. 3, pp. 382-394.

Pfeffer, J. and Nowak, P. (1976), "Joint ventures and interorganizational interdependence", *Administrative Science Quarterly*, Vol. 21 No. 3, pp. 398-418.

Pfeffer, J. and Salancik, G.R. (2003), *The External Control of Organizations: A Resource Dependence Perspective*, Stanford University Press.

Polanyi, M. (1966), The Tacit Dimension Doubleday and Co, Garden City, New York, NY.

Quinn, J.B. (1999), "Strategic outsourcing: leveraging knowledge capabilities", *MIT Sloan Management Review*, Vol. 40 No. 4, p. 9.

Reeder, G.D. and Brewer, M.B. (1979), "A schematic model of dispositional attribution in interpersonal perception", *Psychological Review*, Vol. 86 No. 1, p. 61.

Santoro, G., Bresciani, S. and Papa, A. (2020), "Collaborative modes with cultural and creative industries and innovation performance: the moderating role of heterogeneous sources of knowledge and absorptive capacity", *Technovation*, Vols 92/93, p. 102040.

Santoro, G., Thrassou, A., Bresciani, S. and Del Giudice, M. (2019), "Do knowledge management and dynamic capabilities affect ambidextrous entrepreneurial intensity and firms' performance?", *IEEE Transactions on Engineering Management*, IEEE.

Schnackenberg, A.K. and Tomlinson, E.C. (2016), "Organizational transparency: a new perspective on managing trust in organization-stakeholder relationships", *Journal of Management*, Vol. 42 No. 7, pp. 1784-1810.

Schoenherr, T., Griffith, D.A. and Chandra, A. (2014), "Knowledge management in supply chains: the role of explicit and tacit knowledge", *Journal of Business Logistics*, Vol. 35 No. 2, pp. 121-135.

Scuotto, V., Del Giudice, M., Bresciani, S. and Meissner, D. (2017), "Knowledge-driven preferences in informal inbound open innovation modes. An explorative view on small to medium enterprises", *Journal of Knowledge Management*, Vol. 21 No. 3, pp. 640-655.

Spiller, S.A., Fitzsimons, G.J., Lynch, J.G., Jr. and McClelland, G.H. (2013), "Spotlights, floodlights, and the magic number zero: simple effects tests in moderated regression", *Journal of Marketing Research*, Vol. 50 No. 2, pp. 277-288.

Staubus, G.J. (2005), "Ethics failures in corporate financial reporting", *Journal of Business Ethics*, Vol. 57 No. 1, pp. 5-15.

Thomas, S. (2002), "Firm diversification and asymmetric information: evidence from analysts' forecasts and earnings announcements", *Journal of Financial Economics*, Vol. 64 No. 3, pp. 373-396.

Weber, R.P. (1990), Basic Content Analysis, Sage.

Wei, J., Ouyang, Z. and Chen, H. (2017), "Well known or well liked? The effects of corporate reputation on firm value at the onset of a corporate crisis", *Strategic Management Journal*, Vol. 38 No. 10, pp. 2103-2120.

Weiner, B. (2006), Social Motivation, Justice, and the Moral Emotions: An Attributional Approach, Psychology Press.

Xu, J., Wei, J. and Lu, L. (2019), "Strategic stakeholder management, environmental corporate social responsibility engagement, and financial performance of stigmatized firms derived from Chinese special environmental policy", *Business Strategy and the Environment*, Vol. 28 No. 6, pp. 1027-1044.

Yu, T., Sengul, M. and Lester, R.H. (2008), "Misery loves company: the spread of negative impacts resulting from an organizational crisis", *Academy of Management Review*, Vol. 33 No. 2, pp. 452-472.

Zavyalova, A., Pfarrer, M.D., Reger, R.K. and Shapiro, D.L. (2012), "Managing the message: the effects of firm actions and industry spillovers on media coverage following wrongdoing", *Academy of Management Journal*, Vol. 55 No. 5, pp. 1079-1101.

Corresponding author

Jiuchang Wei can be contacted at: weijc@ustc.edu.cn

Appendix

2 Environmental pollution incident 2013.6.19 Steath pollution 600 600 600 600 600 600 600 600 600 60	Ю.	Event name	Event time	Event type	Stock cod
Security of the product of the content of the con	1	Gree recalled 2.25 million dehumidifiers in a \$150m lawsuit	2013.9.13	Product defects	000651
Security of the product of the content of the con	2	Environmental pollution incident	2013.8.11	Stealth pollution	000629
4 Witamin cyinqiao tablet incident 5 Witamin cyinqiao tablet incident 6 Witamin cyinqiao tablet incident 7 Witamin cyinqiao tablet incident 7 Witamin cyinqiao tablet incident 7 Witamin cyinqiao tablet incident 8 Torigentang mercury incident 8 Torigentang mercury incident 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 Winana bayac contains poison 10 CCTV exposed vitamin C yinqiao tablets containing poison 10 CCTV exposed vitamin C yinqiao tablets containing poison 11 CCTV exposed vitamin C yinqiao tablets containing poison 12 Say Product harms 12 Winana balayac contains poison 12 Say Product harms 12 Say people died in the accident 12 Oli emulsification event 12 Say people died in the accident 12 Winana balats were exposed character unqualified 13 Six people died in the accident 14 Say people died in the accident 15 Say people died in the accident production process 16 Six people died in the accident production process 17 A safety accident occurred in the production process 18 Food coliform group exceeds standard door 19 Network speed is unusually slow 19 Network speed is unusually slow 20 Contamination accident 20 Unqualified drugs	3				600596
5 Vitamin cyinqiao tablet incident 7 Toxic wastewater leaks have brought aquaculture to a standstill 7 Toxic wastewater leaks have brought aquaculture to a standstill 8 Tongrentang mercury incident 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 Tournan baiyao contains poison	4	•		'	002424
3 Vitamin c yinqiao tablet incident 7 Toxic wastewater leaks have brought aquaculture to a standstill 8 Tongrentang mercury incident 8 Tongrentang mercury incident 9 Tongrentang mercury incident 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 The quality of the medicine is not up to standard 9 Tunnan bayao contains poison 10 CCTV exposed vitamin C yinqiao tablets containing poison 10 CCTV exposed vitamin C yinqiao tablets containing poison 11 CCTV exposed vitamin C yinqiao tablets containing poison 12 Tunnan bayao contains poison 12 Tunnan bayao contains poison 13 Environmental pollution events cause cancer 14 Oil emulsification event 15 Six people died in the accident 15 Six people died in the accident 16 Gynecological qianjin tablets were exposed character unqualified 17 Eventoria quality accident occurred in the production process 18 Food coliform group exceeds standard door 18 Food coliform group exceeds standard door 19 Network speed is unusually slow 19 Tonduct defects 10 Contamination accident 19 Unqualified drugs 10 Contamination accident 19 Unqualified drugs 10 Unqualifie	5				600750
7 Toxic wastewater leaks have brought aquaculture to a standstill 2013.6.18 Environment spill 601 30 Tongrentang mercury incident 2013.5.6 Product defects 600 31 The quality of the medicine is not up to standard 2013.5.6 Product defects 600 32 The quality of the medicine is not up to standard 2013.5.6 Product harms 600 32 Tunnan baiyao contains poison 2013.2.2 Malicious rumors 600 33 Environmental pollution events cause cancer 2013.2.2 Malicious rumors 600 34 Oil emulsification event 2013.2.2 Malicious rumors 600 35 Six people died in the accident 2013.2.2 Product defects 000 36 Gynecological qianjin tablets were exposed character unqualified 2013.1.0 Product defects 600 37 A safely accident occurred in the production process 2013.1.0 Product defects 600 38 Food coliform group exceeds standard door 2013.10.1 Product defects 600 39 Network speed is unusually slow 2013.10.1 Product defects 600 40 Unqualified drugs 2013.1.0 Product defects 600 41 Unqualified drugs 2013.1.0 Product defects 600 42 Unqualified drugs 2013.1.0 Product defects 600 43 Unqualified drugs 2013.1.0 Product defects 600 44 Oil environment spill 600 45 The quality of the medicine is in question 2013.1.1 Product defects 600 46 Cement is mixed with other substances 2013.1.1 Product defects 600 47 Recall of bad drugs 2013.1.2 Product defects 600 48 Student milk poisoning incident 2013.4.2 Product defects 600 49 Student milk poisoning incident 2012.8.2 Product defects 600 50 The quality of the medicine is in question 2013.4.2 Product defects 600 51 The quality of the medicine is one past of the product harms 600 51 The quality of the medicine is one past 600 52 The quality problem event 2012.8.2 Product defects 600 53 Student milk poisoning incident 2012.8.2 Product harms 600 54 The quality problem event 2012.8.2 Product defects 600 55 The quality problem event 2012.8.2 Product defects 600 56 The quality problem event 2012.8.2 Product defects 600 57 The quality problem event 2012.8.2 Product defects 600 58 Regional products quality problem event 20	6				600594
3 Tongrentang mercury incident 3 The quality of the medicine is not up to standard 3 The quality of the medicine is not up to standard 3 The quality of the medicine is not up to standard 3 The quality of the medicine is not up to standard 3 The quality of the medicine is not up to standard 4 The quality of the medicine is not up to standard 5 The quality of the medicine is not up to standard 6 The quality of the medicine is not up to standard 7 A safety accident occurred in the production process 8 The quality of the medicine is in question 9 Tongualitied drugs 9 Unqualified drug	7				601899
2013.5.6 Product defects 600 Zhengtian pills toxic incident 2013.4.17 Product harms 000 CTV exposed vitamin C yinqiao tablets containing poison 2013.2.5 Malicious rumors 000 Tunnan baiyao contains poison 2013.2.5 Steath pollution 600 Environmental pollution events cause cancer 2013.2.28 Steath pollution 600 Environmental pollution events 2013.2.28 Steath pollution 600 Six people died in the accident 2013.12.21 Technical accidents 000 Six people died in the accident 2013.12.21 Technical accidents 000 Gynecological qianjin tablets were exposed character unqualified 2013.10.9 Product defects 600 A safety accident occurred in the production process 2013.10.15 Technical accidents 000 Food collorm group exceeds standard door 2013.10.15 Product barms 600 Network speed is unusually slow 2013.10.15 Product defects 600 Contamination accident 2013.10.15 Product defects 600 Unqualified drugs 2013.1.6 Product defects 600 Unqualified drugs 2013.1.6 Product defects 600 Unqualified drugs 2013.1.7 Product defects 600 Unqualified drugs 2013.1.7 Product defects 600 The quality of the medicine is in question 2013.1.17 Product defects 600 Recall of bad drugs 2013.1.2 Product defects 600 Recall of bad drugs 2013.1.17 Product defects 600 Recall of bad drugs 2013.1.17 Product defects 600 Sharki fenjiu is suspected of deliberately concealing the recall 2012.8.2 Product defects 600 Recall of bad drugs 2012.9.14 Product defects 600 Sharki fenjiu is suspected of deliberately concealing the recall 2012.8.2 Product defects 600 Sharki fenjiu is suspected of deliberately concealing the recall 2012.8.2 Product defects 600 Production process safety accident 2012.8.2 Product defects 600 Production process safety accident 2012.8.2 Product defects 600 Drug quality problem event 2012.8.2 Malicious rumors 600 Drug quality problem event 2012.8.2 Malicious rumors 600 Drug quality proble	8			'	600085
0 Zhenglian pills toxic incident CCTV exposed vitamin C yinqia tablets containing poison CCTV exposed vitamin C yinqia tablets containing poison 2013.2.38 Product harms 600 Viunnan balyao contains poison 2013.2.5 Malicious rumors 000. 3 Fire privirormental pollution events cause cancer 2013.2.20 Product defects 000 Oil emulsification event 001.5 Six people died in the accident 001.5 Six people died in the accident 002.3.2.20 Product defects 003.1.2.21 Technical accidents 003.1.2.21 Technical accidents 004.0 Product defects 005.0 Six people died in the accident and production process 007.0 A safety accident occurred in the production process 008.1 Food colliform group exceeds standard door 009.0 Network speed is unusually slow 009.0 Contamination accident 009.0 Network speed is unusually slow 0109.0 Contamination accident 0109.0 Liquualified drugs 0109.0 Recall of back trugs 0109.0 Recall defects 0109.0 Malicious rumors 0109.0 Malicious rumors 0109.0 Malicious rumors 0109.0 Malicious rumors 0109.0 Production process safety accident 0109.0 Production process safety accident 0109.0 Recall defects 0109.0 Production process accident 0109.0 Recall defects 0109.0 Recall defects 0109.0 Malicious rumors 0109.0 Recall defects 0109	9				600666
1 CCTV exposed vitamin C yinqiao tablets containing poison 2013.3.28 Product harms 600. 2013.2.29 Yunnan baiyao contains poison 2013.2.28 Steath pollution of Environmental pollution events cause cancer 2013.2.28 Steath pollution 600. 2013.2.29 Steath pollution 600. 2013.2.20 Product defects 000 environmental pollution event 2013.2.20 Product defects 000 environmental pollution event 2013.2.20 Product defects 000 environmental pollution event 2013.10.3.20 Product defects 600 Product defects 900 Product Product Product Defects 900 Product Defects 900 Product Defects 900 Product Product Defects 900 Product Pro	0				000999
2 Yunnan bajyao contains poison 3 Environmental pollution events cause cancer 2013-2.28 Stealth pollution 4 Oil emulsification event 5 Six people died in the accident 6 Six people died in the accident 7 A safety accident occurred in the production process 7 A safety accident occurred in the production process 8 Food coliform group exceeds standard door 9 Network speed is unusually slow 10 Contamination accident 10 Unqualified drugs 10 Unqualified drugs 10 Unqualified drugs 20 Unqualified					600332
3 Environmental pollution event 3 Collemulsification event 4 Oil emulsification event 5 Six people died in the accident 5 Six people died in the accident 6 Gynecological qianjin tablets were exposed character unqualified 7 A safety accident occurred in the production process 8 Food coliform group exceeds standard door 9 Network speed is unusually slow 9 Network speed is unusually slow 9 Contamination accident 9 Contamination accident 9 Contamination accident 9 Unqualified drugs 9 Contamination accident 1 Unqualified drugs 1 Unqualified drugs 1 Unqualified drugs 1 Unqualified drugs 2 Contamination accident 1 Unqualified drugs 1 Unqualified drugs 2 Contamination accident 2 Unqualified drugs 2 Contamination accident 2 Unqualified drugs 2 Contamination 2 Contami					000538
4 Oil emulsification event 5 Six people died in the accident 6 Gynecological qianjin tabilets were exposed character unqualified 7 A safety accident occurred in the production process 8 2013.10.25 8 Food coliform group exceeds standard door 9 Network speed is unusually slow 2013.10.16 10 Product defects 800 11 Unqualified drugs 2013.10.15 11 Unqualified drugs 2013.1.16 12 Unqualified drugs 2013.1.17 13 Unqualified drugs 2013.1.17 14 Product defects 2013.1.17 15 Product defects 2013.1.17 16 Product defects 2013.1.17 20 Unqualified drugs 2013.1.17 20 Product defects 2010.2.22 20 Product defects 2012.2.22 20 Product defects 2012.2.22 20 Product defects 2012.2.22 20 Product defects 20 Unqualified 20 Unqualif					600362
5 Six people died in the accident 6 Gynecological qianjin tablets were exposed character unqualified 2013.10.29 Product defects 600 7 A safety accident occurred in the production process 2013.10.16 Product defects 600 8 Food coliform group exceeds standard door 2013.10.16 Product harms 600 9 Network speed is unusually slow 2013.10.16 Product defects 600 10 Contamination accident 2013.10.13 Environment spill 600 11 Unqualified drugs 2013.10.15 Product defects 600 12 Unqualified drugs 2013.1.29 Product defects 600 13 Unqualified drugs 2013.1.17 Product defects 600 14 Cement is mixed with other substances 2013.1.17 Product defects 000 15 Unqualified drugs 2013.1.17 Product defects 000 16 Cement is mixed with other substances 2013.1.17 Product defects 000 17 Recall of bad drugs 2013.1.29 Product defects 002 18 Student milk poisoning incident 2012.9.94 Product defects 002 19 Student milk poisoning incident 2012.9.94 Product defects 002 10 Student milk poisoning incident 2012.9.94 Product defects 002 10 Stanxi fenjiu is suspected of deliberately concealing the recall 2012.8.27 Organizational misdeed 000 10 Liquor blending scandal 2012.8.22 Product harms 600 11 Rongshida electric saucepan spot-check unqualified 2012.8.22 Product defects 600 12 Product oprocess safety accident 2012.7.28 Product defects 600 18 Bright dairy products quality problems 2012.7.17 Product defects 600 19 Product oprocess safety accident 2012.7.28 Product defects 600 10 Drug quality of steel causes problemes 2012.7.17 Product defects 600 10 Drug quality problem event 2012.6.26 Product tampering 600 10 Drug quality problem event 2012.6.26 Product tampering 600 10 Drug quality problem event 2012.6.26 Product tampering 600 10 Drug quality problem event 2012.6.26 Malicious rumors 600 10 Drug quality problem event 2012.6.26 Malicious rumors 600 10 Drug quality problem event 2012.6.26 Product harms 900 10 Drug quality problem event 2012.6.29 Malicious rumors 600 19 Drug quality problem event 2012.6.29 Product tampering 600 10 Drug quality problem eve				'	
36 Gynecological qianjin tablets were exposed character unqualified 2013.10.9 Product defects 600 37 A safety accident occurred in the production process 2013.10.15 Technical accidents 000 38 Food coliform group exceeds standard door 2013.10.15 Product defects 600 39 Network speed is unusually slow 2013.10.15 Product defects 600 40 Unqualified drugs 2013.1.6 Product defects 600 51 Unqualified drugs 2013.1.7 Product defects 600 60 Unqualified drugs 2013.1.17 Product defects 600 61 Unqualified drugs 2013.1.17 Malicious rumors 000 62 Unqualified drugs 2013.1.17 Malicious rumors 000 63 Student milk poisoning incident 2012.9.22 Product defects 600 64 Cement is mixed with other substances 2013.1.17 Malicious rumors 000 65 The quality of the medicine is in question 2013.4.26 product defects 600 66 The quality of the medicine is in question 2012.9.22 product defects 600 67 Recall of bad drugs 2012.9.24 Product defects 600					
7 A safety accident occurred in the production process 7 Food coliform group exceeds standard door 8 Food coliform group exceeds standard door 9 Network speed is unusually slow 10 Contamination accident 10 Inqualified drugs 10 Unqualified d					
Food coliform group exceeds standard door 2013.10.16 Product harms 600 Product defects 600. Contamination accident 2013.10.15 Product defects 600. Contamination accident 2013.10.16 Environment spill 600 Unqualified drugs 2013.1.6 Product defects 600 Unqualified drugs 2013.1.6 Product defects 600 Unqualified drugs 2013.1.17 Product defects 000 Unqualified drugs 2013.1.17 Malicious rumors 000 The quality of the medicine is in question 2013.1.17 Malicious rumors 000 Student milk poisoning incident 2012.9.22 Product defects 002 Student milk poisoning incident 2012.9.22 Product defects 002 Student milk poisoning incident 2012.9.22 Product defects 002 Student milk poisoning incident 2012.8.23 Product harms 600 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.27 Organizational misdeed 600 Unqualified 2012.8.22 Product defects 002 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.22 Product defects 003 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.22 Product defects 003 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.22 Product defects 003 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.27 Organizational misdeed 003 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.22 Product defects 003 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.22 Product defects 003 Shanxi fenjiu is suspected of deliberately concealing the recall 2012.7.28 Product defects 003 Shanxi fenjiu products quality problems 2012.7.28 Technical accidents 003 Shanxi fenjiu products quality problems 2012.7.17 Product defects 003 Shanxi fenjiu products quality problems 2012.7.17 Product defects 003 Shanyi pharmaceutical's norfloxacin capsule drug dissolution test 2012.7.17 Product defects 003 Shanyi pharmaceutical's norfloxacin capsule drug dissolution test 2012.7.17 Product defects 003 Drug quality problem event 2012.5.26 Malicious rumors 003 Drug quality problem event 2012.5.26 Malicious rumor					
Network speed is unusually slow 2013.10.15 Product defects 600 Contamination accident 2013.10.13 Environment spill 600 Unqualified drugs 2013.1.6 Product defects 600 Unqualified drugs 2013.1.2 Product defects 000 Unqualified drugs 2013.1.17 Product defects 000 Unqualified drugs 2013.1.29 Product defects 000 Unqualified Unqualifi					
Ontamination accident 2013.10.13 Environment spill 600 Unqualified drugs 2013.1.6 Product defects 600 20 Unqualified drugs 2013.1.17 Product defects 600 2013.1.29 Product defects 900 2013.1.27 Product defects 900 2013.1.17 Product defects 900 2013.1.17 Malicious rumors 900 2013.4.26 product defects 900 2012.9.21 Product defects 900 2012.9.22 Product defects 900 2012.9.22 Product defects 900 2012.9.21 Product defects 900 2012.9.21 Product defects 900 2012.8.20 Product defects 900 2012.8.21 Product defects 900 2012.8.21 Product defects 900 2012.8.21 Product defects 900 2012.8.21 Product defects 900 2012.8.22 Product defects 900 2012.8.22 Product defects 900 2012.8.22 Product defects 900 2012.8.22 Product defects 900 2012.7.28 Product defects 900 2012.7.21 Product defects 900 2012.7.17 Product defects 900 2012.7.18 Product defects 900 2012.7.17 Product defects 900 2012.7.18 Product defects 900 2012.7.19 Product defects 900 20		o i			
Unqualified drugs Unqualified drugs Unqualified drugs 2013.1.22 Product defects 000 Unqualified drugs 2013.1.17 Malicious rumors 000 The quality of the medicine is in question 2013.4.26 product defects 002 Student milk poisoning incident 2012.9.22 Product defects 600 Recall of bad drugs 2012.9.14 Product harms 600 Shanxi fenjul is suspected of deliberately concealing the recall 2012.8.30 Malicious rumors 600 Shanxi fenjul is suspected of deliberately concealing the recall 2012.8.22 Product defects 600 Production process safety accident 2012.8.22 Product defects 600 Production process safety accident 2012.8.22 Product defects 600 Bright dairy products quality problems 2012.7.28 Technical accidents 600 Bright dairy products quality problems 2012.7.21 Product defects 600 The quality of steel causes problems 2012.7.17 Product defects 600 Kangmei pharmaceutical's norfloxacin capsule drug dissolution test 2012.7.17 Product defects 600 Froductiname vent 2012.6.26 Product harms 000 Capality problem event 2012.6.26 Product harms 000 Drug quality problem event 2012.6.27 Product tampering 000 Drug quality problem event 2012.5.28 Malicious rumors 600 Drug quality problem event 2012.5.27 Product tampering 000 Drug quality problem event 2012.5.26 Product harms 000 Drug quality problem event 2012.5.26 Product harms 002 Drug quality problem event 2012.5.26 Product harms 002 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.27 Malicious rumors 600 Drug quality problem event 2012.5.28 Malicious rumors 600 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.27 Malicious rumors 600 Drug quality problem event 2012.5.28 Malicious rumors 600					
Unqualified drugs Unqualified drugs 2013.1.17 Product defects 000 Unqualified drugs 2013.1.17 Product defects 000 Unqualified drugs 2013.1.17 Product defects 000 The quality of the medicine is in question The quality of the medicine is in question Unqualified drugs 2013.4.26 product defects 002 Student milk poisoning incident 2012.9.22 product defects 600 Recall of bad drugs 2012.8.30 Malicious rumors 600 The gutter oil incident Unqualified search and product defects 002 Sharxi fenjiu is suspected of deliberately concealing the recall Unqualified 2012.8.27 Organizational misdeded 003 Rongshida electric saucepan spot-check unqualified Unqualified 2012.8.22 Product harms 000 Rongshida electric saucepan spot-check unqualified 2012.8.22 Product defects 000 Rongshida electric saucepan spot-check unqualified 2012.7.28 Technical accidents 000 Bright dairy products quality problems 2012.7.21 Product defects 000 The PH value of qingrejiedu oral solution was not up to standard 001.7.18 Product defects 000 Kangmei pharmaceutical's norfloxacin capsule drug dissolution test 1012.7.17 Product tampering 000 Kangmei pharmaceutical's norfloxacin capsule drug dissolution test 1012.6.26 Product harms 000 Drug quality problem event 0012.6.26 Product harms 000 Drug quality problem event 0012.6.27 Product tampering 000 Drug quality problem event 0012.5.28 Malicious rumors 000 Drug quality problem event 0012.5.27 Product tampering 000 Drug quality problem event 0012.5.26 product harms 002 Drug quality problem event 0012.5.26 Product tampering 002 Drug quality problem event 0012.5.26 Malicious rumors 002 Drug quality problem event 0012.5.26 Product tampering 002 Drug quality problem event 0012.5.26 Product tampering 003 Drug quality problem event 0012.5.26 Malicious rumors 002 Drug quality problem event 0012.5.26 Malicious rumors 002 Drug quality problem event 0012.5.27 Product tampering 002 Drug quality problem event 0012.5.29 Malicious rumors 002 Drug quality problem event 0012.4.29 Malicious rumors 002 Drug quality problem event 00				•	60042
Unqualified drugs Cement is mixed with other substances Cement is quality product defects Cement is mixed with other substances Cement is quality product defects Cement is quality problem event					60042
Cement is mixed with other substances The quality of the medicine is in question The quality of the medicine is in question Student milk poisoning incident Product defects Control of the quality of the medicine is in question Recall of bad drugs The gutter oil incident Control of the gutter oil					00065
The quality of the medicine is in question Student milk poisoning incident Student milk poisoning incident Recall of bad drugs The gutter oil incident The gutter oil incident Shanxi fenjiu is suspected of deliberately concealing the recall Liquor blending scandal Rongshida electric saucepan spot-check unqualified Production process safety accident The PH value of qingrejiedu oral solution was not up to standard The quality of steel causes problems The quality problem event The quality problem event The quality problem event Thug are are are are are are ar					00089
Student milk poisoning incident					00040
Recall of bad drugs The gutter oil incident The gutter oil incident Shanxi fenjiu is suspected of deliberately concealing the recall Liquor blending scandal Ciquor blending scandal Rongshida electric saucepan spot-check unqualified Production process safety accident The Product quality problems The quality of steel causes problems The quality of steel causes problems The quality of steel causes problems The quality problem event T		· · ·		•	00242
The gutter oil incident 2012.8.30 Malicious rumors 600: Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.27 Organizational misdeed 600: Liquor blending scandal 2012.8.22 Product harms 000: Rongshida electric saucepan spot-check unqualified 2012.8.2 Product defects 600: Production process safety accident 2012.7.28 Technical accidents 600: Right dairy products quality problems 2012.7.21 Product defects 600: The PH value of qingrejiedu oral solution was not up to standard 2012.7.18 Product defects 600: The quality of steel causes problems 2012.7.17 Product tampering 600: Kangmei pharmaceutical's norfloxacin capsule drug dissolution test results were not up to standard 700.000 prog quality problem event 2012.6.16 Malicious rumors 600: Pork quality problem event 2012.6.15 Malicious rumors 600: Drug quality problem event 2012.5.28 Malicious rumors 600: Drug quality problem event 2012.5.28 Malicious rumors 600: Drug quality problem event 2012.5.27 Product tampering 000: Drug quality problem event 2012.5.26 Product harms 600: Drug quality problem event 2012.5.26 Malicious rumors 600: Drug quality problem event 2012.5.24 Malicious rumors 600: Drug quality problem event 2012.5.24 Malicious rumors 600: Drug quality problem event 2012.5.24 Malicious rumors 600: Drug quality problem event 2012.4.29 Malicious rumors 600: D					60012
Shanxi fenjiu is suspected of deliberately concealing the recall 2012.8.27 Organizational misdeed 6000 Liquor blending scandal 2012.8.22 Product harms 0000 Rongshida electric saucepan spot-check unqualified 2012.8.2 Product defects 6000 2012.7.28 Technical accidents 6000 2012.7.28 Technical accidents 6000 2012.7.21 Product of group spirit dairy products quality problems 2012.7.21 Product defects 6000 2012.7.21 Product defects 6000 2012.7.21 Product defects 6000 2012.7.18 Product defects 6000 2012.7.17 Product defects 2012.7.19 P			2012.9.14	Product harms	60019
Liquor blending scandal Rongshida electric saucepan spot-check unqualified Production process safety accident Bright dairy products quality problems Capability of steel causes problems Capability or of steel causes Capability Capability Capabilit			2012.8.30		60038
Rongshida electric saucepan spot-check unqualified 2012.8.2 Product defects 600 Production process safety accident 2012.7.28 Technical accidents 600 Bright dairy products quality problems 2012.7.11 Product defects 600 The PH value of qingrejiedu oral solution was not up to standard 2012.7.18 Product defects 600 The quality of steel causes problems 2012.7.17 Product tampering 600 Kangmei pharmaceutical's norfloxacin capsule drug dissolution test results were not up to standard 7 Drug quality problem event 2012.6.15 Malicious rumors 600 Drug quality problem event 2012.6.15 Malicious rumors 600 Drug quality problem event 2012.5.28 Malicious rumors 600 Drug quality problem event 2012.5.27 Product tampering 000 Drug quality problem event 2012.5.27 Malicious rumors 600 Drug quality problem event 2012.5.27 Product tampering 000 Drug quality problem event 2012.5.27 Malicious rumors 600 Drug quality problem event 2012.5.26 product harms 000 Drug quality problem event 2012.5.26 product harms 000 Drug quality problem event 2012.5.26 product harms 000 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.24 Malicious rumors 600 Drug quality problem event 2012.5.24 Malicious rumors 600 Drug quality problem event 2012.5.24 Malicious rumors 600 Drug quality problem event 2012.4.29 Malicious rumors 600 Drug			2012.8.27	Organizational misdeed	60080
Production process safety accident Bright dairy products quality problems Product defects			2012.8.22	Product harms	00059
Bright dairy products quality problems The PH value of qingrejiedu oral solution was not up to standard The quality of steel causes problems The quality of steel causes problems Rangmei pharmaceutical's norfloxacin capsule drug dissolution test results were not up to standard Trug quality problem event Pork quality problem event Drug quality p	l	Rongshida electric saucepan spot-check unqualified	2012.8.2	Product defects	60098
The PH value of qingrejiedu oral solution was not up to standard The quality of steel causes problems The quality of steel causes problems Kangmei pharmaceutical's norfloxacin capsule drug dissolution test results were not up to standard Thurst were not up to standard Thurst quality problem event Thurst q	2	Production process safety accident	2012.7.28	Technical accidents	60011
The quality of steel causes problems Kangmei pharmaceutical's norfloxacin capsule drug dissolution test results were not up to standard Drug quality problem event Drug quality problem event Pork quality problem event Drug quality problem event	3	Bright dairy products quality problems	2012.7.21	Product defects	60059
Kangmei pharmaceutical's norfloxacin capsule drug dissolution test results were not up to standard Turug quality problem event Drug quality problem event	1	The PH value of qingrejiedu oral solution was not up to standard	2012.7.18	Product defects	60012
results were not up to standard Drug quality problem event Drug quality problem event Drug quality problem event Drug quality problem Drug quality problem event	5	The quality of steel causes problems	2012.7.17	Product tampering	60056
Drug quality problem event 2012.6.26 Product harms 0000 Pork quality problem event 2012.6.15 Malicious rumors 6000 Pork quality problem event 2012.5.28 Malicious rumors 6000 Drug quality problem event 2012.5.28 Malicious rumors 6000 Drug quality problem event 2012.5.27 Product tampering 0000 Product tampering 2012.5.27 Product tampering 2012.5.27 Product tampering 2012.5.27 Product tampering 2012.5.28 Drug quality problem event 2012.5.26 product harms 0000 Product tampering 2012.5.26 Product harms 0000 Product tampering 2012.5.26 Product harms 0000 Drug quality problem event 2012.5.26 Malicious rumors 0000 Drug quality problem event 2012.5.26 Malicious rumors 6000 Drug quality problem event 2012.5.26 Malicious rumors 6000 Drug quality problem event 2012.5.26 Malicious rumors 6000 Drug quality problem event 2012.5.24 Malicious rumors 6000 Drug quality problem event 2012.5.29 Product tampering 6000 Drug quality problem event 2012.4.29 Malicious rumors 6000 Drug quality pr	6	Kangmei pharmaceutical's norfloxacin capsule drug dissolution test	2012.7.17	Product defects	60051
Drug quality problem event Pork quality problem Drug quality problem Drug quality problem Drug quality problem event		results were not up to standard			
Drug quality problem event Pork quality problem Drug quality problem Drug quality problem Drug quality problem event	,	Drug quality problem event	2012.6.26	Product harms	00091
Pork quality problem Drug quality problem event	,	Drug quality problem event	2012.6.15	Malicious rumors	60005
Drug quality problem event 2012.5.27 Product tampering 0000 2012.5.27 Malicious rumors 6000 2012.5.26 product harms 0000 2012.5.26 Malicious rumors 0000 2012.5.27 Malicious rumors 0000 2012.5.29 Product tampering 0000 2012.5.2 Product tampering 0000 2012.5.2 Product tampering 0000 2012.4.29 Malicious rumors 00000 2012.4.29 Malicious rumors 000000 2012.4.29 Product defects 000000000000000000000000000000000000			2012.6.12	Product harms	60088
Drug quality problem event 2012.5.27 Product tampering 0000 2012.5.27 Malicious rumors 6000 2012.5.26 product harms 0000 2012.5.26 Malicious rumors 0000 2012.5.27 Malicious rumors 0000 2012.5.29 Product tampering 0000 2012.5.2 Product tampering 0000 2012.5.2 Product tampering 0000 2012.4.29 Malicious rumors 00000 2012.4.29 Malicious rumors 000000 2012.4.29 Product defects 000000000000000000000000000000000000)		2012.5.28	Malicious rumors	60025
Drug quality problem event 2012.5.27 Malicious rumors 6000 product harms 2012.5.26 product harmors 2012.5.			2012.5.27	Product tampering	00089
Drug quality problem event 2012.5.26 product harms 0000 prug quality problem event 2012.5.26 Product harms 0020 prug quality problem event 2012.5.26 Malicious rumors 6000 prug quality problem event 2012.5.26 Malicious rumors 6000 prug quality problem event 2012.5.26 Malicious rumors 6000 prug quality problem event 2012.5.24 Malicious rumors 6000 Sanjing oral liquid showed foreign body 2012.5.2 Product tampering 6000 prug quality problem event 2012.4.29 Malicious rumors 0020 prug quality problem event 2012.4.29 Malicious rumors 6000 prug quality problem event 2012.4.29 Product defects 6000 prug quality problem event 2012.4.24 Product defects		- · · · · · · · · · · · · · · · · · · ·		' '	60046
Drug quality problem event 2012.5.26 Product harms 002 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.24 Malicious rumors 600 Sanjing oral liquid showed foreign body 2012.5.2 Product tampering 600 Drug quality problem event 2012.4.29 Malicious rumors 002 Drug quality problem event 2012.4.29 Malicious rumors 600 Drug quality problem event 2012.4.29 Product defects 6000	3			product harms	00052
Drug quality problem event 2012.5.26 Malicious rumors 60000 Malicious rumors 6000000 Malicious rumors 60000 Malicious rumors 600000 Malicious rumors 60000 Malicious rumors 600000 Malicious rumors 60000 Malicious r				Product harms	00264
Drug quality problem event 2012.5.26 Malicious rumors 6000 2012.5.26 Malicious rumors 6000 2012.5.24 Malicious rumors 6000 2012.5.24 Malicious rumors 6000 2012.5.2 Product tampering 6000 2012.5.2 Product tampering 6000 2012.4.29 Malicious rumors 6000 201					00237
Drug quality problem event 2012.5.26 Malicious rumors 600 Drug quality problem event 2012.5.24 Malicious rumors 600 Sanjing oral liquid showed foreign body 2012.5.2 Product tampering 600 Drug quality problem event 2012.4.29 Malicious rumors 600 Drug quality problem event 2012.4.29 Malicious rumors 600 Drug quality problem event 2012.4.29 Malicious rumors 600 Drug quality problem event 2012.4.29 Product defects 600					60066
Drug quality problem event 2012.5.24 Malicious rumors 6000 Sanjing oral liquid showed foreign body 2012.5.2 Product tampering 6000 Drug quality problem event 2012.4.29 Malicious rumors 60000 Drug quality problem event 2012.4.29 Product defects 6000000000000000000000000000000000000					60078
Sanjing oral liquid showed foreign body Drug quality problem event		- · · · · · · · · · · · · · · · · · · ·			60055
Drug quality problem event 2012.4.29 Malicious rumors 002: Drug quality problem event 2012.4.29 Malicious rumors 600: Drug quality problem event 2012.4.29 Malicious rumors 002: Drug quality problem event 2012.4.29 Product defects 600:					60082
Drug quality problem event 2012.4.29 Malicious rumors 6002 2 Drug quality problem event 2012.4.29 Malicious rumors 0022 3 Drug quality problem event 2012.4.24 Product defects 6002				, 0	00002
Prug quality problem event 2012.4.29 Malicious rumors 002. Brug quality problem event 2012.4.24 Product defects 600.					
Drug quality problem event 2012.4.24 Product defects 600					00239
		Drug quality problem event	2012.4.24	r roduct defects	(continu

Tabl	e A1			
No.	Event name	Event time	Event type	Stock code
54	Drug quality problem event	2012.4.15	Product harms	000766
55	Production safety accident	2012.2.23	Technical accidents	600019
56	Production safety accident	2012.2.20	Technical accidents	000898
57	Vanke toxic floor incident	2012.2.16	Product harms	000002
58	Plasticizer storm	2012.12.4	Malicious rumors	600519
59	Milk quality problems	2012.12.27	Product harms	600429
60	Environmental pollution event	2012.12.25	Environment spill	000568
61	Environmental pollution event	2012.12.10	Stealth pollution	000488
62	Environmental pollution event	2012.1.3	Stealth pollution	600267
63	The subway crash events	2011.9.27	Technical accidents	600834
64 65	Production safety accident	2011.9.17	Technical accidents	601898
66	Environmental pollution event Employee strike	2011.6.5 2011.5.6	Stealth pollution Technical accidents	600664 000591
67	Production safety accident	2011.5.20	Technical accidents	600228
68	Taking bribes	2011.3.20	Malicious rumors	6000220
69	Ten people died in the industrial accident	2011.3.29	Malicious rumors	600408
70	Shuanghui "clenbuterol" incident	2011.3.15	Product harms	000895
71	Eight people died in the industrial accident	2011.3.12	Technical accidents	600333
72	Drug quality problem	2011.2.11	Technical accidents	300086
73	Vaccine incident	2011.12.8	Product defects	600132
74	Environmental pollution event	2011.12.28	Stealth pollution	002365
75	Production safety accident	2011.11.9	Technical accidents	000553
76	Production safety accident	2011.11.3	Technical accidents	600403
77	Plasticizer exceed the standard in liquor	2011.11.19	Product harms	000799
78	Production safety accident	2011.10.5	Technical accidents	600282
79	Production safety accident	2011.10.19	Technical accidents	002217
80	Production safety accident	2011.10.17	Technical accidents	000157
81	Machine quality problem	2011.10.13	Product defects	002032
82 83	Quality problem of stainless steel products	2011.10.11 2010.8.17	Product defects	600285
84	Production safety accident The efficacy of drugs is questioned	2010.8.17	Technical accidents Product defects	002113 000538
85	Electrical quality problem	2010.7.10	Product defects Product defects	000556
86	Production safety accident	2010.6.29	Technical accidents	000051
87	Production safety accident	2010.6.13	Technical accidents	601666
88	Electrical quality problem	2010.5.23	Product tampering	000527
89	Drug quality problem event	2010.4.15	Product harms	600297
90	Financial fraud crisis	2010.3.30	Financial fraud	600202
91	Production safety accident	2010.3.28	Technical accidents	601898
92	Environmental pollution events	2010.10.21	Environment spill	000060
93	Drug quality problem event	2009.7.23	Product defects	600750
94	Production safety accident	2009.7.11	Technical accidents	000709
95	Housing quality defect	2009.4.8	Product defects	600048
96	Collapse accident	2009.3.24	Technical accidents	000950
97	Production safety accident	2009.3.23	Technical accidents	600096
98	Drug quality problem event	2009.2.6	Product harms	600535
99	Production safety accident	2009.2.22	Technical accidents	000983
100	Product marketing problems	2009.12.24 2008.9.4	Organizational misdeed Technical accidents	600588
101	Death by electric leakage event Vanke donation event	2008.9.4	Malicious rumors	000533 000002
102	China Eastern turning back event	2008.3.13	Organizational misdeed	600115
104	Production safety accident	2008.3.27	Technical accidents	600505
105	Drug quality problem event	2014.3.22	Product tampering	000423
106	Production safety accident	2014.8.27	technical accidents	000488
107	Yunnan baiyao "cross-provincial investigation" incident	2014.7.17	Organizational misdeed	000538
108	Production safety accident	2014.1.7	Technical accidents	000552
109	Drug quality problem event	2014.1.2	Product tampering	000566
110	Automobile quality problem	2014.3.15	Product defects	000625
				(continued)

Tabl	e A1			
No.	Event name	Event time	Event type	Stock code
111	Production safety accident	2014.6.8	Technical accidents	000693
112	Production safety accident	2014.4.29	Technical accidents	000789
113	Plasticizer storm	2014.8.4	Product tampering	000799
114	Bidding fraud	2014.10.8	Organizational misdeed	000801
115	Production safety accident	2014.2.8	Technical accidents	002114
116	Buried carcinogens exposed event	2014.2.17	Organizational misdeed	002440
117	Product quality problem	2014.2.25	Malicious rumors	002570
118 119	Improper trading and CSRC investigation Environmental pollution event	2014.12.9 2014.6.9	Malicious rumors Malicious rumors	600051 600059
120	Environmental pollution event	2014.1.7	Environment spill	600267
121	Environmental pollution event	2014.11.4	environment spill	600746
122	Environmental pollution event	2014.12.25	Stealth pollution	600789
123	Selling fake products	2014.3.12	Organizational misdeed	601258
124	Customer rights protection event	2014.6.11	Organizational misdeed	601519
125	False record of financial data	2018.10.18	Organizational misdeed	600112
126	Swine flu	2018.10.15	Malicious rumors	002385
127 128	The Yangtze alligator nature reserve was invaded	2018.10.12 2018.8.28	Technical accidents Technical accidents	002230 000782
129	Employees were killed Environmental pollution event	2018.8.14	Stealth pollution	600298
130	Environmental pollution event	2018.8.14	Stealth pollution	002105
131	Illegal guarantee event	2018.7.31	Malicious rumors	000752
132	Vaccine fraud incident	2018.7.15	Product tampering	002680
133	Boli international "backup" storm	2018.6.5	Disputes accidents	300135
134	U.S. government procurement ban	2018.5.24	Malicious rumors	002583
135	Environmental pollution event	2018.4.20	Stealth pollution	002496
136	Environmental pollution event	2018.4.17	Stealth pollution	000755
137 138	Suspected of dropping dead seedlings	2018.2.22 2018.1.12	Malicious rumors	002069 000799
139	Product packaging infringement Accused of copying American technology	2018.1.12	Disputes accidents Organizational misdeed	601558
140	The efficacy of benzidarine eye drops was questionable	2017.12.22	Product harms	603168
141	Production safety accident	2017.12.19	Technical accidents	300214
142	Investor suit	2017.5.12	Organizational misdeed	002323
143	Investor suit	2017.8.4	Organizational misdeed	002200
144	Improper trading and CSRC investigation	2017.7.27	Organizational misdeed	600775
145	Break a contract and CSRC investigation	2017.7.26	Organizational misdeed	000712
146	Short swing trading and CSRC investigation	2017.7.25	organizational misdeed	000651
147 148	Improper trading and CSRC investigation	2017.7.24 2017.7.23	Malicious rumors Malicious rumors	600873 600233
149	Employees are not paid on time Executive resignations	2017.7.23	Organizational misdeed	600233
150	Insider trading	2017.7.17	Organizational misdeed	600055
151	Improper trading and CSRC investigation	2017.6.26	Malicious rumors	600761
152	Insider trading	2017.6.15	Organizational misdeed	002454
153	Short swing trading and CSRC investigation	2017.6.14	Organizational misdeed	002508
154	Improper trading and CSRC investigation	2016.12.29	Organizational misdeed	300135
155	Audit non-standard opinions and CSRC investigation	2017.4.6	Financial fraud	002490
156	Financial information disclosure violations	2017.2.6	Financial fraud	002263
157	Chinese medicinal materials were exposed dyeing adulterated	2017.1.17	Product tampering	600479
158 159	African swine fever virus was detected in feed samples Contract fraud	2018.11.11 2018.10.26	product harms Organizational misdeed	002567 600240
160	Investor suit	2018.9.21	Financial fraud	600576
161	False record of financial information	2018.4.17	Financial fraud	600576
162	Financial information fraud	2018.9.13	Financial fraud	002501
163	Financial information fraud and CSRC investigation	2018.9.11	Malicious rumors	603777
164	Improper trading and CSRC investigation	2018.8.30	Organizational misdeed	000883
165	Executives arrested and CSRC investigation	2018.8.25	Financial fraud	300310
166	Senior executives committed serious violations of discipline and law	2018.8.24	Organizational misdeed	000858
167	Improper trading and CSRC investigation	2018.8.22	Disputes accidents	600408
				(continued)

Tabl	e A1			
No.	Event name	Event time	Event type	Stock code
168	Environmental pollution event	2018.8.15	Malicious rumors	600874
169	Illegal stock pledge business and investor suit	2018.8.15	Financial fraud	600909
170	Contract fraud and executives arrested	2018.8.8	Organizational misdeed	002164
171	The valsartan API was detected by NDMA	2018.8.4	Product harms	002923
172	The valsartan API was detected by NDMA	2018.8.4	Product harms	300702
173	The valsartan API was detected by NDMA	2018.7.6	Product harms	600521
174	Insider trading	2018.7.20	Organizational misdeed	300030
175	Contract fraud and executives arrested	2018.7.17	Malicious rumors	600310
176	Illegal guarantee event	2018.7.13	Disputes accidents	000662
177	Production safety accident	2018.2.6	Technical accidents	000717
178	Production safety accident	2018.2.10	Technical accidents	000717
179	Investor suit	2018.6.14	Organizational misdeed	002562
180	Financial information disclosure is illegal	2018.5.10	Financial fraud	002473
181	Executives were killed	2018.5.7	Disputes accidents	000899
182	Environmental pollution event	2018.5.2	Stealth pollution	002496
183	Financial information disclosure is illegal	2018.1.28	Financial fraud	002628
184	Executive resignations together	2017.12.19	Organizational misdeed	002323
185	Financial information fraud and CSRC investigation	2017.12.16	Financial fraud	002288
186	Production management defect	2017.11.28	Technical accidents	300106
187	Financial information disclosure is illegal	2017.10.12	Financial fraud	300531
188	Illegal guarantee event	2017.10.11	Organizational misdeed	600745
189	Short swing trading and CSRC investigation	2017.8.11	Organizational misdeed	600139
190	Spreading misleading information	2017.8.10	Technical accidents	300033
191	Insider trading and CSRC investigation	2017.7.20	Organizational misdeed	002161
192	Executive resignations together	2016.11.30	Malicious rumors	000430
193	Insider trading and CSRC investigation	2016.11.7	Organizational misdeed	000012
194	Financial information disclosure is illegal	2016.11.10	Organizational misdeed	600802
195	Drug quality problem event	2016.7.19	Product harms	600332
196	Financial information disclosure is illegal	2016.4.4	Organizational misdeed	600812
197	Falsification of clinical data	2015.12.8	Organizational misdeed	300404
198	Falsification of clinical data	2015.12.8	Organizational misdeed	300347
199	Environmental pollution event	2015.9.21	Malicious rumors	002294
200	Financial information disclosure is illegal	2015.7.21	Organizational misdeed	600781
201	Illegal use of project land and CSRC investigation	2015.3.30	Disputes accidents	600211
202	Executives committed serious disciplinary violations	2016.3.15	Organizational misdeed	600519
203	Illegal production and sales	2015.3.6	Organizational misdeed	002030

Tab	Table A2 Corporate information	_									
No.	Firm name	Event	Time to market	Industry	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
-	Gree Electric Appliances Inc.	2013.9.13	1996.11.18	C38	Electrical machinery and equipment manufacturing	000651	7.50	107.57	108.05	74.36	201
~	Panzhihua steel group panel Co. Ltd.	2013.8.11	1996.11.15	C32	Nonferrous metal smelting and rolling processing	000629	3.84	31.06	15.27	50.45	200
ო	Zhejiang xin 'an chemical industry group co. Ltd.	2013.6.19	2001.9.6	C26	Manufacturing of chemical materials and products	962009	2.38	7.24	6.58	39.17	141
4	Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd.	2013.6.18	2010.6.3	C27	Pharmacy	002424	16.73	3.24	1.40	36.96	36
2	Jiangzhong Pharmaceutical 2013.6.18 Co., Ltd.	2013.6.18	1996.9.23	C27	Pharmacy	600750	7.11	3.23	2.77	14.76	200
9	Guizhou Yibai Pharmaceutical Co., Ltd.	2013.6.18	2004.3.23	C27	Pharmacy	600594	15.04	2.28	2.78	32.12	110
_	Zijin Mining Group Co., Ltd.	2013.6.18	2008.4.25	B09	Nonferrous metal mining	601899	12.71	67.35	49.77	50.14	61
∞	Tongrentang Chinese Medicine Co., Ltd.	2013.5.7	1997.6.25	C27	Pharmacy	600085	11.71	9.67	7.50	42.03	190
0	Southwest Pharmaceutical Co., Ltd.	2013.5.6	1993.7.12	C27	Pharmacy	999009	2.95	1.51	1.20	71.44	237
10	China Resources Sanjiu Pharmaceutical Co., Ltd.	2013.4.17	2000.3.9	C27	Pharmacy	666000	15.69	8.61	6.87	35.26	157
Ξ	Guangzhou Baiyunshan Pharmaceutical Co., Ltd.	2013.3.28	2001.2.6	C27	Pharmacy	600332	4.96	6.24	8.13	32.25	145
											(continued)

api	l able A2										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
12	Yunnan Baiyao Group Co., Ltd.	2013.2.5	1993.12.15	C27	Pharmacy	000538	11.56	10.66	13.64	34.10	229
5	Jiangxi Copper Industry Co., Ltd.	2013.2.28	2002.1.11	C32	Nonferrous metal smelting and rolling processing	600362	3.34	78.13	158.16	43.80	133
4	Chongqing Changan Automobile Co., Ltd.	2013.2.20	1997.6.10	C36	Motor	000625	4.80	46.12	37.74	59.48	188
15	Hubei Yihua Group Co., Ltd. 2013.12.21	2013.12.21	1996.8.15	C26	Manufacturing of chemical materials and products	000422	7.62	29.65	18.91	73.48	208
16	Zhuzhou Qianjin Pharmaceutical Co., Ltd.	2013.10.9	2004.3.12	C27	Pharmacy	600479	8.27%	1.65	1.96	35.33	114
17	Hubei Sanonda Co., Ltd.	2013.10.25	1993.12.3	C26	Manufacturing of chemical materials and products	000553	4.45	2.41	3.49	47.42	238
18	China Southern Airlines Group Co., Ltd.	2013.10.16	2003.7.25	G56	Air transport	600059	3.74	142.49	96.35	72.21	122
19	Chengdu Dr. Peng Telecom 2013.10.15 Media Group Co., Ltd.	2013.10.15	1994.1.3	164	Internet and related services	600804	8.12	8.67	0.83	56.44	237
20	Kunyao Pharmaceutical Group Co., Ltd.	2013.10.13	2000.12.6	C27	Pharmacy	600422	%29.9	2.15	3.56	50.89	154
21	Shanghai Hyundai Pharmaceutical Co., Ltd.	2013.1.6	2004.6.16	C27	Pharmacy	600420	7.56	2.47	0.72	51.78	102
22	Renhe Pharmaceutical Co., Ltd.	2013.1.22	1996.12.10	C27	Pharmacy	0000650	13.23	5.09	2.07	18.27	193
											(continued)

No. Firm name Event ime to market Industry code frm type Stock code (%) Profitability 23 Henan Shuanghui 2013.1.17 1998.12.10 C13 Farm and sideline food o00895 7.73 24 Tangshuanghui 2013.1.17 1996.6.14 C30 Mandischine food o00895 7.73 25 Tangshuan Johng Cement 2013.4.28 2010.6.3 C27 Pharmacy 002422 18.58 26 Jinjian Rice Industry Co., Ltd. 2012.9.2 1998.5.6 C13 Pharmacy 600196 21.35% 27 Found Pharmacy 600196 21.35% 28 Jinjian Rice Industry Co., Ltd. 2012.8.3 2001.6.8 C27 Pharmacy 600196 21.35% 29 Shanxi Fen Wine Co., Ltd. 2012.8.2 1996.9.2 C27 Pharmacy 600896 17.12 29 Shanxi Fen Wine Co., Ltd. 2012.8.2 1996.9.2 C35 Pharmacy 600896 17.12 29 Shanxi Fen Wine Co., Ltd. 2012.8.2 2004.7.2	<u> </u>	Table A2										
Henan Shuanghui 2013.1.17 1998.12.10 C13 Farm and sideline food processing processing processing co., Ltd. 000401 Co., Ltd. Tangshan Jidong Cement 2013.1.17 1996.6.14 C30 Manufacture of non-metallic mineral products 000401 Sichuan Kelun Sichuan Kelun 2012.9.22 1998.5.6 C13 Pharmacy 002422 1 Jinjian Rice Industry Co., Ltd. 2012.9.14 1998.8.7 C27 Pharmacy 600196 2 Ltd. Fosun Pharmaceutical Co., Ltd. 2012.8.30 2001.6.8 C27 Pharmacy 600196 2 Ltd. Joincare Pharmaceutical Co., Ltd. 2012.8.27 1994.1.6 C15 Pharmacy 600380 1 Joincare Pharmaceutical Co., Ltd. 2012.8.27 1994.1.6 C15 Wine, beverage and refined tea manufacturing 600890 2 Group Industry Co., Ltd. 2012.8.2 1996.9.27 C15 Wine, beverage and refined tea manufacturing 600893 1 Hefei Rongshida Sanyo 2012.7.28 1996.9.27 C38 Electrical medial smelling	No		Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
Tangshan Jidong Cement 2013.1.17 1996.6.14 C30 Manufacture of non-metallic mineral products 000401 Co., Ltd. Sichuan Kelun Co., Ltd. 2013.4.26 2010.6.3 C27 Pharmacy Pharmacy Pharmacy Pharmacy Pharmacy Injian Rice Industry Co., Ltd. 1998.5.6 C13 Farm and sideline food Foot 600127 114d. Joincare Pharmaceutical Co., Ltd. 2012.8.30 2001.6.8 C27 Pharmacy Foot Pharmacy Foot Googs Goods Go	23	Henan Shuanghui Investment Development Co., Ltd.	2013.1.17	1998.12.10	C13	Farm and sideline food processing	000895	7.73	16.70	40.58	24.80	169
Sichuan Kelun 2013.4.26 2010.6.3 C27 Pharmacy 002422 Pharmaceutical Co., Ltd. 2012.9.22 1998.5.6 C13 Farm and sideline food foot 27 00127 Ltd. Joincare Pharmaceutical Co., Ltd. 2012.8.30 2001.6.8 C27 Pharmacy 600380 Group Industry Co., Ltd. 2012.8.27 1994.1.6 C15 Wine, beverage and refined tea manufacturing 600809 Gujing Gong Wine Co., Ltd. 2012.8.2 1996.9.27 C15 Wine, beverage and refined tea manufacturing 000596 Hefei Rongshida Sanyo 2012.8.2 1996.9.27 C15 Wine, beverage and requipment 600983 Hicki Rongshida Sanyo 2012.8.2 2004.7.27 C38 Electrical machinery and equipment 600983 Xining Special Steel Co., Ltd. 2012.7.28 1997.10.15 C31 Ferrous metal smelting 600177 Ltd. 2012.7.28 1997.10.15 C31 Food manufacturing 600597	24	Tangshan Jidong Cement Co., Ltd.	2013.1.17	1996.6.14	C30	Manufacture of non- metallic mineral products	000401	0.94%	41.50	4.36	67.80	199
Jinjian Rice Industry Co., Jud. 2012.9.22 1998.5.6 C13 Farm and sideline food processing processing 600127 Ltd. Fosun Pharmaceutical Co., Ltd. Solutions are Pharmaceutical Co., Ltd. Shanxi Fen Wine Co., Ltd. 2012.8.2 2001.6.8 C27 Pharmacy Fonds 600196 Gujing Gong Wine Co., Ltd. Shanxi Fen Wine F	25	Sichuan Kelun Pharmaceutical Co., Ltd.	2013.4.26	2010.6.3	C27	Pharmacy	002422	18.58	14.93	5.88	39.29	34
Fosun Pharmaceutical Co., Ltd. 2012.9.14 1998.8.7 (27 Pharmacy Ltd. C27 Pharmacy Co. Ltd. 600196 G00380 Group Industry Co., Ltd. 2012.8.27 1994.1.6 (215 Wine, beverage and manufacturing Group Wine Co., Ltd. 2012.8.27 (1996.9.27 (215 Wine, beverage and manufacturing Mine, beverage and manufacturing Gujing Gong Wine Co., Ltd. 600809 Hefei Rongshida Sanyo 2012.8.2 (2004.7.27 (238 Electrical machinery Electric Co., Ltd. 2012.8.2 (2004.7.27 (238 Electrical machinery manufacturing and rolling processing Guangming dairy co., Ltd. 600177 (231 Ferrous metal smelting and rolling processing Guangming dairy co., Ltd. 2012.7.21 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Food manufacturing Guangming dairy co., Ltd. 600597 (2002.8.28 (214 Foo	26	Jinjian Rice Industry Co., Ltd.	2012.9.22	1998.5.6	C13	Farm and sideline food processing	600127	-4.96	1.39	1.44	44.71	172
Joincare Pharmaceutical 2012.8.30 2001.6.8 C27 Pharmacy 600380 Group Industry Co., Ltd. 2012.8.27 1994.1.6 C15 Wine, beverage and manufacturing 600809 Gujing Gong Wine Co., Ltd. 2012.8.22 1996.9.27 C15 Wine, beverage and manufacturing 000596 Hefei Rongshida Sanyo 2012.8.2 2004.7.27 C38 Electrical machinery 600983 Electric Co., Ltd. 2012.7.28 1997.10.15 C31 Ferrous metal smelting 600117 Xining Special Steel Co., Ltd. 2012.7.28 1997.10.15 C31 Ferrous metal smelting 600597 Guangming dairy co., Ltd. 2012.7.21 2002.8.28 C14 Food manufacturing 600597	27	Fosun Pharmaceutical Co., Ltd.		1998.8.7	C27	Pharmacy	600196	21.35%	22.29	7.26	48.99	169
Shanxi Fen Wine Co., Ltd. 2012.8.27 1994.1.6 C15 Wine, beverage and refined tea manufacturing 600809 Gujing Gong Wine Co., Ltd. 2012.8.22 1996.9.27 C15 Wine, beverage and manufacturing 000596 Hefei Rongshida Sanyo 2012.8.2 2004.7.27 C38 Electrical machinery equipment 600983 Xining Special Steel Co., Ltd. 2012.7.28 1997.10.15 C31 Ferrous metal smelting 600117 Ltd. 2012.7.21 2002.8.28 C14 Food manufacturing 600597	28	Joincare Pharmaceutical Group Industry Co., Ltd.	2012.8.30	2001.6.8	C27	Pharmacy	600380	10.25	8.81	0.58	38.06	134
Gujing Gong Wine Co., Ltd. 2012.8.22 1996.9.27 C15 Wine, beverage and refined tea manufacturing 000596 Hefei Rongshida Sanyo 2012.8.2 2004.7.27 C38 Electrical machinery and equipment 600983 Xining Special Steel Co., Ltd. 2012.7.28 1997.10.15 C31 Ferrous metal smelting and rolling processing 600117 Ltd. Guangming dairy co., Ltd. 2012.7.21 2002.8.28 C14 Food manufacturing 600597	29	Shanxi Fen Wine Co., Ltd.	2012.8.27	1994.1.6	C15	Wine, beverage and refined tea manufacturing	608009	20.60	4.91	4.27	25.10	223
Hefei Rongshida Sanyo 2012.8.2 2004.7.27 C38 Electrical machinery 600983 Electric Co., Ltd. Xining Special Steel Co., 2012.7.28 1997.10.15 C31 Ferrous metal smelting 600117 Ltd. Guangming dairy co., Ltd. 2012.7.21 2002.8.28 C14 Food manufacturing 600597	30			1996.9.27	C15	Wine, beverage and refined tea manufacturing	965000	17.12	4.24	4.54	34.91	190
Xining Special Steel Co., 2012.7.28 1997.10.15 C31 Ferrous metal smelting 600117 Ltd. Ltd. Guangming dairy co., Ltd. 2012.7.21 2002.8.28 C14 Food manufacturing 600597	31	Hefei Rongshida Sanyo Electric Co., Ltd.	2012.8.2	2004.7.27	C38	Electrical machinery and equipment manufacturing	600983	8.25	3.72	3.89	64.62	96
Guangming dairy co., Ltd. 2012.7.21 2002.8.28 C14 Food manufacturing 600597	32		2012.7.28	1997.10.15	C31	Ferrous metal smelting and rolling processing	600117	5.95	13.41	9.14	74.68	177
	33		2012.7.21	2002.8.28	O14	Food manufacturing	600597	2.30	7.37	11.58	58.73	118 (continued)

מש	I able As										
No.	Firm name	Event	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock mark (Month)
34	Chongqing Taiji Industry (Group) Co., Ltd.	2012.7.18	1997.11.18	C27	Pharmacy	600129	69:0	7.95	6.54	79.61	176
35	Anyang Iron & Steel Co., Ltd.	2012.7.17	2001.8.20	C31	Ferrous metal smelting and rolling processing	699009	0.12	32.95	20.51	67.04	130
36	Kangmei Pharmaceutical Co., Ltd.	2012.7.17	2001.3.19	C27	Pharmacy	600518	16.53	15.24	11.16	37.00	135
37	Jinling Pharmaceutical Co., Ltd.	2012.6.26	1999.11.18	C27	Pharmacy	000019	9.33	2.96	0.83	21.40	151
38	Zhejiang Guyue Longshan Shaoxing Wine Co., Ltd.	2012.6.15	1997.5.16	C15	Wine, beverage and refined tea manufacturing	690009	13.76	3.09	0.75	26.40	180
39	Inner Mongolia Yili Industrial 2012.6.12 Group Co., Ltd.	2012.6.12	1996.3.12	C14	Food manufacturing	600887	4.89	19.93	37.27	68.36	195
40	Henan Tianfang Pharmaceutical Co., Ltd.	2012.5.28	2000.12.27	C27	Pharmacy	600253	1.41	3.37	1.33	72.29	137
4	Henan Shuanghui Investment Development Co., Ltd.	2012.5.27	1998.12.10	C13	Farm and sideline food processing	000895	1.71	7.84	36.63	44.69	161
42	Sichuan Dikang Technology Pharmaceutical Co., Ltd.	2012.5.27	2001.2.12	C27	Pharmacy	600466	7.42	0.63	0.31	13.44	135
43	Guangzhou Baiyunshan Pharmaceutical Co., Ltd.	2012.5.26	1993.11.8	C27	Pharmacy	000522	7.38	3.15	3.76	55.28	222
44	Lanzhou Foci Pharmaceutical Co., Ltd.	2012.5.26	2011.12.22	C27	Pharmacy	002644	11.82	0.83	0.27	21.84	2
45	Zhejiang Asia Pacific Pharmaceutical Co., Ltd.	2012.5.26	2010.3.16	C27	Pharmacy	002370	10.42	0.87	0.42	14.51	26
											(continued)

Tab	Table A2										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
46	Southwest Pharmaceutical Co., Ltd.	2012.5.26	1993.7.12	C27	Pharmacy	999009	3.55	1.57	0.97	74.79	226
47	Shandong Lukang Pharmaceutical Co., Ltd.	2012.5.26	1997.2.26	C27	Pharmacy	600789	0.81	3.48	2.30	51.35	183
48	Jiangsu Kangyuan Pharmaceutical Co., Ltd.	2012.5.24	2002.9.18	C27	Pharmacy	600557	12.32	2.58	1.54	42.87	116
49	Harbin Pharmaceutical Group Sanjing Pharmaceutical Co Ltd.	2012.5.2	1994.2.24	C27	Pharmacy	600829	10.77	3.84	3.60	49.64	218
20	Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd.	2012.4.29	2010.6.3	C27	Pharmacy	002424	18.44	3.02	0.89	35.72	22
21	Guizhou Yibai Pharmaceutical Co., Ltd.	2012.4.29	2004.3.23	C27	Pharmacy	600594	14.07	1.80	1.90	36.90	26
52	Guizhou Xinbang Pharmaceutical Co., Ltd.	2012.4.29	2010.4.16	C27	Pharmacy	002390	12.68	1.24	0.36	21.23	24
23	Shanghai Fudan Fuhua Technology Co., Ltd.	2012.4.24	1993.1.5	C27	Pharmacy	600624	3.98	1.52	0.72	58.17	231
24	Tonghua Golden-Horse Pharmaceutical Industey Co.Ltd	2012.4.15	1997.4.30	C27	Pharmacy	992000	6.19	0.88	0.00	30.99	179
22	Baoshan Iron and Steel Co., Ltd.	2012.2.23	2000.12.12	C31	Ferrous metal smelting and rolling processing	600019	3.48	231.10	0.22	50.90	134
26	Angang Steel Co., Ltd.	2012.2.20	1997.12.25	C31	Ferrous metal smelting and rolling processing	868000	-2.58	102.99	0.90	49.21	169
22	Vanke Enterprise Co., Ltd.	2012.2.16	1991.1.29	K70	Real estate	000005	16.16	296.21	0.01	77.10	252
											(continued)

No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
28	Guizhou Moutai Co., Ltd.	2012.12.4	2001.8.27	C15	Wine, beverage and refined tea manufacturing	600519	50.27	34.90	18.40	27.21	135
29	Beijing Sanyuan Food Co., Ltd.	2012.12.27	2003.9.15	C14	Food manufacturing	600429	0.66	3.46	3.55	48.59	111
09	Luzhou Laojiao Co., Ltd.	2012.12.25	1994.5.9	C15	Wine, beverage and refined tea manufacturing	000568	36.26	12.48	11.28	42.10	223
61	Shandong Chenming Paper 2012.12.10 Group Co., Ltd.	2012.12.10	2000.11.20	C22	Papermaking and paper products	000488	3.32	45.63	20.15	67.15	144
62	Zhejiang Hisun Pharmaceutical Co., Ltd.	2012.1.3	2000.7.25	C27	Pharmacy	600267	66.6	8.23	2.07	44.19	137
63	Shanghai Shentong Metro Co., Ltd.	2011.9.27	1994.2.24	G54	Road transport	600834	11.23	1.78	0.78	38.35	211
64	China Coal Energy Co., Ltd.	2011.9.17	2008.2.1	B06	Coal Mining	601898	10.62	120.82	88.87	29.22	43
92	Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd.	2011.6.5	1993.6.29	C27	Pharmacy	600664	9.04	11.76	13.49	44.35	215
99	Chongqing Tongjunge Co., Ltd.	2011.5.6	1996.2.8	C27	Pharmacy	000591	0.43	2.30	0.00	76.86	182
29	Jiangxi Changjiu Biochemical Co., Ltd.	2011.5.20	1999.1.19	C26	Manufacturing of chemical materials and products	600228	-14.89	0.94	0.95	79.12	148
89	Sany Heavy Industry Co., Ltd.	2011.4.19	2003.7.3	C35	Special equipment manufacturing	600031	18.15	31.34	0.05	61.97	66
											(continued)

	e in arket h)											(penu
	Tenure in stock marke (Month)	26	147	123	ω	169	21	215	96	172	132	(continued)
	Asset Tenure in liability ratio stock market (%) (Month)	56.89	35.78	40.94	3.99	57.88	6.98	44.5	11.24	41.41	71.17	
	Firm revenue (Billion/ RMB)	4.82	36.63	1.51	0.00	2.61	0.42	1.61	7.69	0.36	38.57	
	Firm asset (Billion/ RMB)	6.81	6.71	2.36	1.90	3.55	1.09	2.01	0.36	1.29	35.21	
	Profitability (%)	0.47	3.92	4.80	44.30	15.02	14.42	1.50	3.71	14.05	3.05	
	Stock code	600408	000895	600333	300086	600132	002365	000553	600403	662000	600282	
	Firm type	Ferrous metal smelting and rolling processing	Farm and sideline food processing	Gas production and supply	Pharmacy	Wine, beverage and refined tea manufacturing	Pharmacy	Manufacturing of chemical materials and products	Coal Mining	Wine, beverage and refined tea manufacturing	Ferrous metal smelting and rolling processing	
	Industry	C31	C13	D45	C27	C15	C27	C26	B06	C15	C31	
	Time to market	2003.2.12	1998.12.10	2000.12.11	2010.5.26	1997.10.30	2010.3.5	1993.12.3	2003.10.9	1997.7.18	2000.9.19	
	Event time	2011.3.29	2011.3.15	2011.3.12	2011.2.11	2011.12.8	2011.12.28	2011.11.9	2011.11.3	2011.11.19	2011.10.5	
9 A 2	Firm name	Shanxi Antai Group Co., Ltd.	Henan Shuanghui Investment Development Co., Ltd.	CHANGCHUN GAS CO., LTD	Kangzhi Pharmaceutical Co., Ltd.	Chongqing Beer Co., Ltd.	Qianjiang Yongan Pharmaceutical Co., Ltd.	Hubei Sanonda Co., Ltd.	Henan Dayou Energy Co., Ltd.	Jiujiu Liquor Co., Ltd.	Nanjing Iron and Steel Co., Ltd.	
Table A2	No.	69	70	71	72	73	74	75	92	27	78	

Tab	Table A2										
N _O	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
62	Shandong United Chemical 2011.10.19 Co., Ltd.	2011.10.19	2008.2.20	C26	Manufacturing of chemical materials and	002217	9.91	1.31	1.13	35.28	43
80	Zoomlion Heavy Industry Co., Ltd.	2011.10.17	2000.10.12	C35	products Special equipment manufacturing	000157	14.25	63.00	0.00	56.39	132
82	Zhejiang Supor Co., Ltd. Henan Lingrui Pharmaceirtical Co. 1 td	2011.10.13	2004.8.17	C33 C27	Metal products Pharmacy	002032	7.88	3.93	7.00	30.37	131
83	Hunan Tianrun Chemical Development Co., Ltd.	2010.8.17	2007.2.8	C26	Manufacturing of chemical materials and products	002113	-19.98	99.0	0.07	44.91	42
84	Yunnan Baiyao Industrial Co., Ltd.	2010.7.16	1993.12.15	C27	Pharmacy	000538	8.49	6.01	0.00	39.56	199
82	Zhuhai Gree Electric Appliance Co., Ltd.	2010.6.29	1996.11.18	C38	Electrical machinery and equipment manufacturing	000651	9.90	51.53	0.00	79.33	163
98	Overseas Chinese Town A Co., Ltd.	2010.6.29	1997.9.10	K70	Realestate	690000	17.01	30.74	10.91	62.76	153
87	Pingdingshan Tianan Coal Industry Co., Ltd.	2010.6.13	2006.11.23	B06	Coal Mining	601666	7.47	15.85	21.63	49.41	42
88	Guangdong Midea Electric Co., Ltd.	2010.5.23	1993.11.12	C38	Electrical machinery and equipment manufacturing	000527	5.32	31.66	0.09	59.80	198
88	Dalian Meiluo Pharmaceutical Co., Ltd.	2010.4.15	2000.11.16	C27	Pharmacy	600297	1.10	1.95	1.03	59.40	112
06	Harbin Air Conditioning Co., Ltd.	, 2010.3.30	1999.6.3	C38	Electrical machinery and equipment manufacturing	600202	13.41	2.87	0.68	63.90	129
91	China Coal Energy Co., Ltd.	2010.3.28	2008.2.1	B06	Coal Mining	601898	13.20	109.68	0.00	29.02	25 (continued)

	Industry
	Event
Table A2	
	ANAGEMENT

lable AZ	e AZ										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
95	Shenzhen Zhongjinlingnan Nonferrous Metals Co., Ltd.	2010.10.21	1997.1.23	C32	Nonferrous metal smelting and rolling processing	090000	6.89	11.65	0.00	59.42	164
93	Jiangzhong Pharmaceutical 2009.7.23 Co., Ltd.	2009.7.23	1996.9.23	C27	Pharmacy	600750	8.88	1.59	2.64	38.88	154
94	Hebei Iron and Steel Co., Ltd.	2009.7.11	1997.4.16	C31	Ferrous metal smelting and rolling processing	602000	3.58	41.52	0.01	68.63	146
92	Poly Real Estate (Group) Co., Ltd.	2009.4.8	2006.7.31	K70	Real estate	600048	19.61	53.63	47.03	70.78	32
96	Chongqing Jianfeng Chemical Co., Ltd.	2009.3.24	1999.9.16	C26	Manufacturing of chemical materials and products	000000	18.82	2.49	3.31	60.49	114
26	Yunnan Yuntianhua Co., Ltd.	2009.3.23	1997.7.9	C26	Manufacturing of chemical materials and products	960009	10.69	17.66	7.99	69.24	140
86	Tianjin Tasly pharmaceutical Co., Ltd.	2009.2.6	2002.8.23	C27	Pharmacy	600535	7.29	3.45	6.54	39.30	77
66	Shanxi Xishan Coal and Electricity Power Co., Ltd.	2009.2.22	2000.7.26	B06	Coal Mining	000983	26.65	17.49	29.85	40.38	102
100	UFIDA Network Technology Co., Ltd.	2009.12.24	2001.5.18	165	Software and information technology services	600588	23.63	3.11	2.45	31.82	103
101	Guangdong Wanjiale Co., Ltd.	2008.9.4	1994.1.3	C38	Electrical machinery and equipment manufacturing	000533	4.11	2.61	0.00	77.33	176
102	Vanke Enterprise Co., Ltd.	2008.5.15	1991.1.29	K70	Real estate	000005	14.97	100.09	0.01	66.11	207 (continued)

l able AZ	g AZ										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
103	China Eastern Airlines Co., Ltd.	2008.3.31	1997.11.5	929	Air transport	600115	1.40	67.14	0.08	94.69	124
104	Jiangxi Changjiu Biochemical Co., Ltd.	2008.3.27	2002.5.30	D44	Electricity and heat production and supply	600505	16.07	1.65	0.55	86.26	69
105	Dong ajiao co., Ltd. Shandong Chenming Paper Group Co., Ltd.	2014.3.22 2014.8.27	1996.7.29	C27 C22	Pharmacy Papermaking and paper products	000423	30.37	5.98	1.13	14.97	211
107	Yunnan Baiyao Group Co., Ltd.	2014.7.17	1993.12.15	C27	Pharmacy	000538	14.68	12.88	16.37	29.91	247
108	Yunnan Baiyao Group Co., Ltd.	2014.1.7	1994.1.6	B06	Coal Mining	000552	11.50	5.73	4.09	54.55	240
109	Hainan Haiyao Co., Ltd. Chongqing Changan Automobile Co., Ltd.	2014.1.2 2014.3.15	1994.5.25 1997.6.10	C27 C36	Pharmacy Motor	000566	9.99	3.47	1.05	54.21	235
-	Chengdu Huaze Cobalt Nickel Materials Co., Ltd.	2014.6.8	1997.2.26	B09	Nonferrous metal mining	69000	2.54	3.41	4.37	65.61	207
112	Jiangxi Wannianqing Cement Co., Ltd.	2014.4.29	1997.9.23	C30	Manufacture of non- metallic mineral products	000789	11.30	7.85	6.17	54.77	199
113	Jiangxi Wannianqing Cement Co., Ltd.	2014.8.4	1997.7.18	C15	Wine, beverage and refined tea manufacturing	000799	-5.67	2.18	0.68	17.92	204
1 4	Sichuan Jiuzhou Electric Co., Ltd.	2014.10.8	1998.5.6	C39	Manufacturing of computers, communications and other electronic equipment	000801	3.06	3.19	2.20	53.96	197
											(continued)

I able AZ	2 Y A										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
115	Chengdu Huaze Cobalt Nickel Materials Co., Ltd.	2014.2.8	2007.2.15	C32	Nonferrous metal smelting and rolling processing	002114	-5.89	1.77	0.81	55.84	83
116	Zhejiang Lutu Co., Ltd.	2014.2.17	2010.7.6	C26	Manufacturing of chemical materials and products	002440	19.30	6.39	4.78	20.70	43
117	Beinmei co., Ltd. Ningbo United Group Co., Ltd.	2014.2.25	2011.4.12	C14 F51	Food manufacturing Wholesale trade	002570	11.79	5.09	90.00	23.16	34
119	Zhejiang Guyue Longshan Shaoxing Wine Co., Ltd.	2014.6.9	1997.5.16	C15	Wine, beverage and refined tea manufacturing	60009	9.88	3.59	0.83	29.85	204
120	Zhejiang Hisun Pharmaceutical Co., Ltd.	2014.1.7	2000.7.25	C27	Pharmacy	600267	2.90	13.97	8.48	57.36	161
121	Jiangsu Thorpe Chemical Co., Ltd.	2014.11.4	1996.9.18	C26	Manufacturing of chemical materials and products	600746	3.81	0.62	0.64	30.22	217
122	Shandong Lukang Pharmaceutical Co., Ltd.	2014.12.25	1997.2.26	C27	Pharmacy	682009	0.19	4.07	2.29	59.88	213
123	Jumbo Auto Trading Group Co., Ltd.	2014.3.12	2011.4.28	F52	Retail	601258	0.34	65.06	63.99	86.01	34
124	Shanghai Great Wisdom Co., Ltd.	2014.6.11	2011.1.28	165	Software and information technology services	601519	-13.65	3.43	0.65	13.54	04
											(continued)

Figure F	lab	I able AZ										
Quizhou Changzheng 2018.10.18 1997.11.27 C38 Electrical machineny and quipment 600112 2.31 2.91 0.56 51.50 Tancheng Holdings Co., Ltd. 2018.10.15 2018.10.15 2010.4.9 C13 Farm and sideline food one casing processing 7.03 19.26 18.74 43.59 Technology Group Co., Ltd. 2018.10.15 2008.5.12 165 Schware and sideline food information technology Group Co., Ltd. 1997.6.19 C28 Schware and sideline food information technology Group Co., Ltd. 1997.6.19 C28 Chemical fiber on manufacturing Group Co., Ltd. 000782 1.03 2.88 3.81 43.70 Angel yeastroo., Ltd. 2018.14 2007.1.12 C3 C14 Food manufacturing Group Co., Ltd. 000782 1.03 2.46 1.45 1.75 65.27 Industry Development Co., Ltd. 1997.6.25 C15 Wine, beverage and other transport equipment 1.60 1.45 1.75 62.37 Changsheng Biotechnology 2018.5.24 2010.10.26 C25 Pharmacy 002680 36.54 4.51 1.75	No.	Firm name	Event time	Time to market	Industry code		Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Tenure in stock market (Month)
Beijing Dabeinong 2018.10.15 2010.4.9 C13 Farm and sideline food 002386 7.03 19.26 18.74 43.59 Technology Group Co., Ltd. 2018.10.12 2008.5.12 165 Software and processing 002230 8.80 13.34 5.44 43.70 Oingdao Highly Media Co., Ltd. 2018.8.28 1997.6.19 C28 Chemical fiber 000782 1.03 2.63 3.81 5.45 Ltd. 2018.8.14 2000.8.18 C18 C74 1.03 2.63 3.81 5.52 Shearble stronglogy 2018.8.14 2007.1.12 C37 Manufacturing of mortal endinger and other transport equipment 1.66 8.03 8.69 50.30 Ltd. 2018.7.15 2018.7.15 2018.7.15 C37 Pharmacy 1.29 1.59 1.1.19 Chargsheng Biotechnology 2018.7.15 2010.10.26 C25 Pharmacy 1.29 3.07 1.80 60.74 Chargsheng Biotechnology 2018.5.24 2010.10.26 C25 Pharmacy 0	125		2018.10.18	1997.11.27	C38	Electrical machinery and equipment manufacturing	600112	2.31	2.91	0.56	51.50	250
FLYTEK CC., LTD. 2018.10.12 2008.5.12 165 Software and office mation technology and against the manufacturing of a product and activity of a product activity of a product and activity of a product a	126	ш,	2018.10.15	2010.4.9	C13	Farm and sideline food processing	002385	7.03	19.26	18.74	43.59	102
Gingdao Highly Media Co., Ltd. 2018.8.28 (1997.6.19) C28 (Chemical fiber on 000782 (1.03) 1.03 (2.63) 3.81 (5.45) 2.63 (3.81) 2.64 (3.81) 2.64 (3.81) 2.64 (3.81) 2.64 (3.81) 2.64 (3.81) 2.64 (3.81) 2.65 (3.81) 2.64 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) 2.65 (3.81) <	127	IFLYTEK CO., LTD.	2018.10.12	2008.5.12	165	Software and information technology services	002230	8.80	13.34	5.44	43.70	125
Angel yeast co., Ltd. 2018.8.14 2000.8.18 C14 Food manufacturing of Sharzhen Xinlong Health 2018.8.14 2007.1.12 C37 Manufacturing of Shenzhen Xinlong Health 2018.7.31 1997.6.25 C15 Wine, beverage and other Tibet Yinhe Technology 2018.7.31 1997.6.25 C15 Wine, beverage and other Tibet Yinhe Technology 2018.7.15 2012.6.5 C27 Pharmacy 002680 36.54 4.51 1.55 13.97 Co., Ltd. Jiangsu Baoil International 2018.6.5 2010.10.26 C26 Manufacturing of Shenzhent Co., Ltd. Jiangsu Baoil International 2018.6.5 2010.10.26 C39 Manufacturing of Shenzhent Co., Ltd. Shenzhent Co., Ltd. Computers. Co., Ltd. Co	128		2018.8.28	1997.6.19	C28	Chemical fiber manufacturing	000782	1.03	2.63	3.81	54.52	254
Tibet Yinhe Technology 2018.7.31 1997.6.25 C15 Wine, beverage and refined tea manufacturing 000752 12.38 1.50 0.36 11.19 2 Development Co., Ltd. Changsheng Biotechnology 2018.6.5 C27 Pharmacy manufacturing of co., Ltd. 300136 3.654 4.51 1.55 13.97 Co., Ltd. Jiangsu Baoli International Co., Ltd. C26 Manufacturing of products 300136 1.99 3.07 1.80 60.74 Hytera Communications 2018.5.24 2011.5.27 C39 Manufacturing of communications and other electronic equipment 002583 4.58 13.93 5.35 58.63	130		2018.8.14	2000.8.18	C14 C37	Food manufacturing Manufacturing of railways, ships, aerospace and other transport equipment	600298	15.46 2.46	8.03	6.69	50.30	215 139
Changsheng Biotechnology 2012.6.5 C27 Pharmacy 002680 36.54 4.51 1.55 13.97 Co., Ltd. Jiangsu Baoli International Jangsu Baoli International Sament Co., Ltd. 2016.6.5 2010.10.26 C26 Manufacturing of chemical materials and products 1.99 3.07 1.80 60.74 Hytera Communications 2018.5.24 2011.5.27 C39 Manufacturing of computers, communications and other electronic equipment 002583 4.58 13.93 5.35 58.63	131	Tibet Yinhe Technology Development Co., Ltd.	2018.7.31	1997.6.25	C15	Wine, beverage and refined tea manufacturing	000752	12.38	1.50	0.36	11.19	253
Jiangsu Baoli International 2018.6.5 2010.10.26 C26 Manufacturing of chemical materials and products 300135 1.99 3.07 1.80 60.74 Investment Co., Ltd. chemical materials and products products 4.58 13.93 5.35 58.63 Co., Ltd. communications and other electronic equipment communications and other electronic equipment	132			2012.6.5	C27	Pharmacy	002680	36.54	4.51	1.55	13.97	73
Hytera Communications 2018.5.24 2011.5.27 C39 Manufacturing of 002583 4.58 13.93 5.35 58.63 Co., Ltd. communications and other electronic equipment	133	·	2018.6.5	2010.10.26	C26	Manufacturing of chemical materials and products	300135	1.99	3.07	1.80	60.74	91
	134		2018.5.24	2011.5.27	C 39	Manufacturing of computers, communications and other electronic equipment	002583	4.58	13.93	5.35	58.63	83

(continued)

No.	<i>Firm name</i>	Event	Time to market	Industry code	ndustry code Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
135	Jiangsu Huifeng Agricultural Chemical Co., I td	2018.4.20	2010.11.9	C26	Manufacturing of chemical materials and products	002496	11.02	8.12	3.95	46.62	68
136	Shanxi Road and Bridge Co., Ltd.	2018.4.17	1997.6.27	G54	Road transport	000755	4.01	2.00	2.29	59.99	249
137	Zhangzidao Group Co., Ltd.	2018.2.22	2006.9.28	A04	Fishery	002069	-22.64	3.94	3.21	89.78	136
138	Jiujiu Liquor Co., Ltd.	2018.1.12	1997.7.18	C15	Wine, beverage and refined tea manufacturing	662000	19.83	2.54	0.88	21.09	245
139	Sinovel Wind Power Technology (Group) Co., Ltd.	2018.1.9	2011.1.13	C34	General machinery manufacturing	601558	81.59	6.71	0.05	80.66	83
140	Zhejiang Shapu Aisi Pharmaceutical Co., Ltd.	2017.12.22	2014.7.2	C27	Pharmacy	603168	28.17	1.84	0.94	10.33	41
141	Shandong Rike Chemical Co., Ltd.	2017.12.19	2011.5.11	C26	Manufacturing of chemical materials and products	300214	5.17	1.48	2.10	8.69	79
142	Jiangsu Yabaite Technology Co., Ltd.	2017.5.12	2009.12.18	E50	Building decoration and other construction	002323	19.10	2.04	1.38	62.30	888
143	Yunnan Yuntou Ecological Environment Technology Co., Ltd.	2017.8.4	2007.12.21	A02	Forestry	002200	6.71	3.44	0.67	72.28	115
											(continued)

<u> </u>	I able Az										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
144	Nanjing Panda Electronics Co., Ltd.	2017.7.27	1996.11.18	C39	Manufacturing of computers, communications and other electronic equipment	600775	4.56	5.24	0.00	36.48	248
145	Guangdong Jinlong Development Co., Ltd.	2017.7.26	1997.4.15	790	Capital market services	000712	81.58	26.17	1.17	82.31	243
146	Zhuhai Gree Electric Appliance Co., Ltd.	2017.7.25	1996.11.18	C38	Electrical machinery and equipment manufacturing	000651	14.33	182.37	148.29	73.82	248
147	Meihua Biotechnology Group Co., Ltd.	2017.7.24	1995.2.17	C14	Food manufacturing	600873	9.62	16.98	11.07	46.65	269
148		2017.7.23	2000.6.8	G60	Mail business	600233	8.16	11.17	0.00	23.18	205
149	Liuzhou Chemical Co., Ltd.	2017.7.17	2003.7.17	C26	Manufacturing of chemical materials and products	600423	-39.31	3.70	1.83	103.14	168
150	Beijing Wandong Medical Equipment Co., Ltd.	2017.7.15	1997.5.19	C35	Special equipment manufacturing	600055	8.41	2.20	0.80	15.30	241
151	Anhui Heli Co., Ltd.	2017.6.26	1996.10.9	C35	Special equipment manufacturing	600761	7.41	6.38	0.00	32.61	248
152	Shanghai Kallang Songzhi Automotive Air Conditioning Co., Ltd.	2017.6.15	2010.7.20	C36	Motor	002454	7.93	4.81	3.24	37.29	85
153		2017.6.14	2010.11.23	C38	Electrical machinery and equipment manufacturing	002508	20.83	6.42	5.79	35.85	28

(continued)

Table A2	e A2										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
154	Jiangsu Baoli International Investment Co., Ltd.	2016.12.29	2010.10.26	C26	Manufacturing of chemical materials and products	300135	1.34	2.79	1.75	59.09	74
155	Shandong Molong Petroleum Machinery Co., Ltd.	2017.4.6	2010.10.21	C35	Special equipment manufacturing	002490	-42.50	5.77	1.53	66.74	77
156	Zhejiang Dadongnan Packing Co., Ltd.	2017.2.6	2008.7.28	C29	Rubber and plastic products	002263	-20.23	3.97	0.95	29.72	102
157	Qianjin Pharmaceutical Co., 2017.1.17 Ltd.	2017.1.17	2004.3.12	C27	Pharmacy	600479	6.05	3.03	2.84	31.27	154
158	Tangrenshen Group Co., Ltd.	2018.11.11	2011.3.25	C13	Farm and sideline food processing	002567	2.81	6.03	13.72	38.09	91
159	Beijing Huaye Capital Holdings Co., Ltd.	2018.10.26	2000.6.28	K70	Real estate	600240	25.77	20.85	3.86	61.70	219
160	Zhejiang Xiangyuan Culture Co., Ltd.	2018.9.21	2003.2.20	R87	Arts and culture	929009	11.67	2.09	0.79	12.81	187
161	Zhejiang Xiangyuan Culture Co., Ltd.	2018.4.17	2003.2.20	R87	Arts and culture	925009	11.67	2.09	0.79	12.81	181
162	Jilin Liyuan Refining Co., Ltd.	2018.9.13	2010.11.17	C32	Nonferrous metal smelting and rolling processing	002501	17.26	15.23	3.03	52.42	83
163	Shanghai Lai Yifen Co., Ltd.	2018.9.11	2016.10.12	F52	Retail Flootricity and beat	603777	2.79	3.00	3.57	28.35	22
† -	Ltd.			7	production and supply		2		- -	2	Q f
											(continued)

No. 165									Firm		
165	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	revenue (Billion/ RMB)	Asset Tenure in liability ratio stock market (%) (Month)	Tenure in stock market (Month)
166	Yitong Century Technology Co., Ltd.	2018.8.25	2012.4.25	163	Telecommunications, broadcast television and satellite transmission services	300310	8.40	4.55	2.58	21.18	92
	Yibin Wuliangye Co., Ltd.	2018.8.24	1998.4.27	C15	Wine, beverage and refined tea manufacturing	000858	33.41	70.92	30.19	27.21	243
167	Shanxi Antai Group Co., Ltd.	2018.8.22	2003.2.12	C31	Ferrous metal smelting and rolling processing	600408	-4.29	5.47	6.32	75.71	186
168	Tianjin Chuangye Environmental Protection Co., Ltd.	2018.8.15	1995.6.30	D46	Water production and supply	600874	24.17	12.45	2.15	55.35	277
169	Huaan Securities Co., Ltd.	2018.8.15	2016.12.6	790	Capital market services	606009	42.30	39.91	1.92	73.11	20
170	Ningbo Dongli Co., Ltd.	2018.8.8	2007.8.23	L72	Commercial service	002164	1.24	16.39	12.87	98.07	131
171	Zhuhai Rundu Pharmaceutical Co., Ltd.	2018.8.4	2018.1.5	C27	Pharmacy	002923	11.63	0.71	0.78	20.05	O
172	Zhejiang Tianyu Pharmaceutical Co., Ltd.	2018.8.4	2017.9.19	C27	Pharmacy	300702	8.43	2.11	1.19	41.61	10
173	Zhejiang Huahai Pharmaceutical Co., Ltd.	2018.7.6	2003.3.4	C27	Pharmacy	600521	12.47	8.27	3.99	46.72	184
174	Guangzhou Yangpu Medical Technology Co., Ltd.	2018.7.20	2009.12.25	C35	Special equipment manufacturing	300030	1.50	1.75	0.55	42.63	102
175	Guangxi Guidong Electric Power Co., Ltd.	2018.7.17	2001.2.28	D44	Electricity and heat production and supply	600310	0.98	12.75	11.93	83.40	208
											(continued)

Tab	Table A2										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
176	Tianxia Smart City Technology Co., Ltd.	2018.7.13	1996.12.16	165	Software and information technology services	000662	34.48	7.11	1.67	18.75	258
177	Guangdong Shaogang Songshan Co., Ltd.	2018.2.6	1997.5.8	C31	Ferrous metal smelting and rolling processing	000717	9.66	14.42	26.04	79.38	248
178	Guangdong Shaogang Songshan Co., Ltd.	2018.2.10	1997.5.8	C31	Ferrous metal smelting and rolling processing	000717	9.66	14.42	26.04	79.38	249
179	Brother Technology Co., Ltd.	2018.6.14	2011.3.10	C27	Pharmacy	002562	25.76	3.47	1.56	34.64	87
180	Ningbo Shengleda Electric Co., Ltd.	2018.5.10	2010.9.10	C38	Electrical machinery and equipment manufacturing	002473	-49.23	0.38	0.12	23.38	92
181	Jiangxi Ganneng Co., Ltd.	2018.5.7	1997.11.26	D44	Electricity and heat production and supply	668000	0.77	7.32	2.13	39.21	245
182	Jiangsu Huifeng Biological Agriculture Co., Ltd.	2018.5.2	2010.11.9	C26	Manufacturing of chemical materials and products	002496	11.02	8.12	3.95	46.62	88
183	Chengdu Road and Bridge Construction (Group) Co., Ltd.	2018.1.28	2011.11.3	E48	Civil engineering construction	002628	1.12	5.60	1.99	52.20	74
184	Jiangsu Yabaite Technology Co., Ltd.	2017.12.19	2009.12.18	E50	Building decoration and other construction	002323	19.10	2.04	1.38	61.92	96 (continued)

r ket							ed)
Tenure in stock marke (Month)	66	87	4	253	233	91	(continued)
Asset Tenure in liability ratio stock market (%) (Month)	41.54	63.87	23.59	70.22	72.99	28.74	
Firm revenue (Billion/ RMB)	1.44	0.69	0.44	16.87	0.29	1.41	
Firm asset (Billion/ RMB)	2.27	2.77	0.64	12.88	6.07	4.08	
Profitability (%)	-7.49	-7.04	20.29	1.43	-16.82	68.89	
Stock code	002288	300106	300531	600745	600139	300033	
Firm type	Manufacturing of computers, communications and other electronic equipment	Graziery	Manufacturing of computers, communications and other electronic equipment	Manufacturing of computers, communications and other electronic equipment	Motor	Software and information technology services	
Industry code	C39	A03	C39	C39	C36	165	
Time to market	2009.9.3	2010.8.20	2016.8.9	1996.8.28	1998.2.25	2009.12.25	
Event time	2017.12.16	2017.11.28	2017.10.12	2017.10.11	2017.8.11	2017.8.10	
Firm name	Guangdong Chaohua Technology Co., Ltd.	Xinjiang Western Animal Husbandry Co., Ltd.	Shenzhen Youboxun Technology Co., Ltd.	Wingtech Technology Co., Ltd.	Sichuan Western Resources Holdings Co., Ltd.	Zhejiang Nuclear New Flush 2017.8.10 Network Information Co., Ltd.	
No.	185	186	187	188	189	190	

Tabl	Table A2										
No.	Firm name	Event time	Time to market	Industry code	Firm type	Stock code	Profitability (%)	Firm asset (Billion/ RMB)	Firm revenue (Billion/ RMB)	Asset liability ratio (%)	Asset Tenure in liability ratio stock market (%) (Month)
191	Shenzhen Yuanwanggu Information Technology Co., Ltd.	2017.7.20	2007.8.21	C39	Manufacturing of computers, communications and other electronic equipment	002161	7.82	2.13	0.51	22.57	118
192	Zhangjiajie Tourism Group Co., Ltd.	2016.11.30	1996.8.29	N78	Public facilities management	000430	16.94	0.87	0.59	51.11	243
193	China CSG Group Co., Ltd.	2016.11.7	1992.2.28	C30	Manufacture of non- metallic mineral products	000012	7.37	15.66	8.97	51.33	296
194	Fujian Cement Co., Ltd.	2016.11.10	1994.1.3	C30	Manufacture of non- metallic mineral products	600802	-35.12	5.05	1.31	71.99	274
195	Guangzhou Baiyunshan Pharmaceutical Co., Ltd.	2016.7.19	2001.2.6	C27	Pharmacy	600332	7.03	15.87	2.48	46.14	185
196	North China Pharmaceutical Co., Ltd.	2016.4.4	1994.1.14	C27	Pharmacy	600812	0.64	16.00	7.80	67.65	266
197	Guangzhou Boji Pharmaceutical Biotechnology Co., Ltd.	2015.12.8	2015.4.24	C27	Pharmacy	300404	20.27	0.52	0.13	16.95	_
198	Hangzhou Tiger Pharmaceutical Technology Co., Ltd.	2015.12.8	2012.8.17	C27	Pharmacy	300347	21.84	4.62	96:0	28.70	36
199	Shenzhen Xinlitai Pharmaceutical Co., Ltd.	2015.9.21	2009.9.10	C27	Pharmacy	002294	36.20	5.39	3.48	13.00	72 (continued)

Tabl	Table A2										
No.	No. Firm name	Event time	Industry Time to market code Firm type	Industry code	Firm type	Profitabili Stock code (%)	Firm asset Profitability (Billion/ (%) RMB)	Firm Firm asset revenue (Billion/ (Billion/ I.	Firm revenue (Billion/ RMB)	ä.	Asset Tenure in bility ratio stock market (%) (Month)
200	Furen Pharmaceutical Group Pharmaceutical Co., Ltd.	2015.7.21	1996.12.18	C27	C27 Pharmacy	600781	3.66	1.07	0.43	63.41	223
201	Tibet Nuodikang Pharmaceutical Co., Ltd.	2015.3.30	1999.7.21	C27	Pharmacy	600211	1.21	1.05	1.66	61.5	188
202	Guizhou Moutai Wine Co., Ltd.	2016.3.15	2001.8.27	C15	Wine, beverage and refined tea manufacturing	600519	50.38	86.30	32.65	37.77	174
203	Sun Yat-sen University Daan Gene Co., Ltd.	2015.3.6	2004.8.9	C27	Pharmacy	002030	14.60	1.59	1.08	50.97	126

Industry (Industry code: R87). Time to Market reveals the time when the firm went public. Profitability means the net profit margin on sales in the year before the crisis. Firm Revenue means the corporate business revenue in the year before the crisis. Tenure in Stock Market means the time interval between the time when the firm went public and the event time Notes: Industry Code reveals main business types of listed companies in this study, including 41 industry types from Forestry Industry (Industry code: A02) to Arts and Culture

Table A3 Regressions of crisis-related cumulative abnormal returns (seven-day CAR)	ed cumulative a	onormal re	eturns (seven-d	ay CAR)						
Variables	Model 1	p-value	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p-value
(Constant) Profitability Tobin's Q Leverage Firm size Firm size Forduct harm Technical accidents Organizational misdeed Return on industry assets Market share Corporate transparency (CT) Unrelated diversification(UD) Attribution of knowledge deficiency (AD) UD*CT UD*AD	-0.049 (0.094) -0.073 (0.073) -0.051 (0.079) 0.075 (0.082) 0.005 (0.083) -0.265 (0.072) -0.202 (0.230) 0.342(0.188) 0.030 (0.191) -0.039(0.076)	0.603 0.315 0.520 0.362 0.955 0.000 0.381 0.070 0.877 0.612	-0.107 (0.095) -0.078 (0.071) -0.056(0.078) -0.020 (0.082) -0.231 (0.071) -0.066 (0.231) 0.308 (0.209) 0.308 (0.209) 0.175(0.085) -0.066 (0.069) 0.175(0.085) -0.0207 (0.077)	0.259 0.277 0.473 0.686 0.809 0.001 0.776 0.102 0.042 0.042 0.087	-0.102 (0.092) -0.062 (0.070) -0.076 (0.076) -0.016 (0.082) -0.011 (0.080) -0.239 (0.069) -0.078 (0.225) 0.361 (0.180) 0.222 (0.265) -0.088 (0.075) 0.186 (0.082) -0.068 (0.068) 0.190 (0.072) -0.152 (0.076)	0.272 0.376 0.306 0.848 0.0889 0.001 0.730 0.0245 0.0245 0.009 0.009	-0.096 (0.094) -0.076 (0.071) -0.066 (0.077) -0.020 (0.081) -0.020 (0.081) -0.024 (0.071) -0.024 (0.071) -0.029 (0.183) 0.278 (0.208) 0.177 (0.084) -0.069 (0.076) 0.119 (0.076) -0.076 (0.069)	0.310 0.281 0.395 0.840 0.0840 0.0693 0.107 0.183 0.376 0.037 0.093 0.006	-0.091 (0.092) -0.061 (0.069) -0.087 (0.075) -0.031 (0.082) -0.011 (0.079) -0.248 (0.069) -0.101 (0.223) 0.353 (0.179) 0.194 (0.224) 0.187 (0.082) -0.086 (0.067) 0.185 (0.071) -0.159 (0.076) 0.243 (0.076)	0.324 0.324 0.250 0.250 0.704 0.888 0.000 0.650 0.050 0.023 0.023 0.010 0.038
PP adj Fadjo	0.125		0.172		0.220		0.191		0.238	
Note: $n = 203$, values in table are unstandardized regression coefficients. Standard errors are in parentheses	z., yo ardized regressior	n coefficien	Standard error	's are in pa	o., so rentheses) - -			

Table A4 Regressions of crisis-related cumulative abnormal returns (three-day CAR, without three dummy variables)	ated cumulative a	bnormal re	eturns (three-da	y CAR, w	ithout three dum	my variak	oles)			
Variables	Model 1	p <i>-value</i>	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p-value
(Constant) Profitability Tobin's Q Leverage Firm size Number of fatalities Return on industry assets Market share Corporate transparency (CT) Unrelated diversification (UD) Attribution of knowledge deficiency(AD) UD*CT UD*AD R² eq; R² adj F-statistic	0.000(0.068) -0.159(0.073) -0.002(0.077) -0.014(0.081) 0.003(0.083) -0.176(0.070) -0.120(0.075) 0.181(0.082)	0.030 0.979 0.979 0.973 0.013 0.013	0.000(0.066) -0.161(0.071) 0.012(0.075) -0.056(0.080) -0.034(0.082) -0.153(0.083) -0.146(0.075) 0.256(0.083) -0.045(0.068) 0.174(0.071) -0.183(0.068)	1.000 0.025 0.870 0.491 0.678 0.053 0.002 0.512 0.015	0.000(0.064) -0.146(0.069) -0.016(0.074) -0.106(0.080) -0.024(0.080) -0.152(0.066) -0.166(0.073) 0.266(0.081) -0.061(0.067) 0.242(0.072) -0.147(0.067) 0.238(0.071)	0.996 0.037 0.826 0.187 0.023 0.002 0.001 0.028 0.001	0.003(0.065) -0.159(0.070) -0.003(0.074) -0.033(0.080) -0.151(0.067) -0.151(0.082) -0.072(0.068) 0.170(0.069) -0.199(0.067) 0.198 0.152 4.296**	0.966 0.024 0.972 0.315 0.015 0.002 0.002 0.003 0.003	0.002(0.063) -0.145(0.068) -0.030(0.073) -0.128(0.079) -0.023(0.078) -0.163(0.065) -0.170(0.072) 0.268(0.080) -0.087(0.066) 0.236(0.071) -0.163(0.066) 0.231(0.070) 0.242 0.194	0.9371 0.035 0.035 0.107 0.766 0.013 0.001 0.001 0.001 0.001 0.001
Notes: $n = 203$, values in table are unstandardized regression coefficients. Standard errors are in parentheses	ndardized regressi	on coefficie	nts. Standard erro	ors are in p	arentheses					

Table As Hegressions of crisis-related cumulative abnormal returns (three-day CAH, alternative measurement of unrelated diversification)	ed cumulative at	onormal r	eturns (three-da	ıy CAH, a	Iternative measi	rement c	or unrelated dive	rsificatio	(`	
Variables	Model 1	p-value	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p-value
(Constant)	0.017 (0.095)	0.861	-0.041 (0.094)	0.663	-0.028 (0.092)	0.763	-0.028 (0.093)	0.761	-0.016 (0.091)	0.863
Profitability	-0.165(0.073)	0.025	-0.169(0.071)	0.018	-0.154(0.070)	0.028	-0.165(0.070)	0.020	-0.150(0.068)	0.030
Tobin's Q	-0.006(0.079)	0.936	-0.015(0.077)	0.850	-0.036(0.076)	0.632	-0.028(0.076)	0.709	-0.049(0.075)	0.512
Leverage	-0.031(0.083)	0.703	-0.087(0.083)	0.294	-0.139(0.082)	0.092	-0.104(0.082)	0.204	-0.154(0.081)	0.059
Firm size	-0.009(0.084)	0.918	-0.039(0.082)	0.636	-0.027(0.080)	0.736	-0.040(0.081)	0.621	-0.028(0.079)	0.719
Number of fatalities	-0.200(0.072)	900.0	-0.163(0.071)	0.022	-0.173(0.069)	0.013	-0.175(0.070)	0.013	-0.184(0.068)	0.007
Product harm	-0.367(0.231)	0.113	-0.237 (0.230)	0.305	-0.257(0.225)	0.254	-0.261(0.227)	0.251	-0.280(0.221)	0.208
Technical accidents	0.142(0.188)	0.452	0.103(0.184)	0.576	0.158 (0.180)	0.381	0.095 (0.181)	0.600	0.149 (0.177)	0.400
Organizational misdeed	-0.023(0.191)	906.0	0.258 (0.208)	0.217	0.165 (0.205)	0.422	0.228 (0.205)	0.268	0.138(0.202)	0.495
Return on industry assets	-0.101(0.076)	0.187	-0.126(0.076)	0.101	-0.149(0.075)	0.048	-0.127(0.075)	0.092	-0.150(0.074)	0.043
Market share	0.208(0.084)	0.014	0.283(0.085)	0.001	0.294 (0.083)	0.000	0.283(0.083)	0.001	0.294(0.081)	0.000
Corporate transparency (CT)			-0.050(0.069)	0.472	-0.056(0.067)	0.405	-0.075(0.069)	0.278	-0.080(0.067)	0.234
Unrelated diversification (UD)			0.177 (0.071)	0.013	0.240(0.072)	0.001	0.174(0.070)	0.013	0.235 (0.071)	0.001
Attribution of knowledge deficiency (AD)			-0.207(0.076)	0.007	-0.151(0.076)	0.049	-0.216(0.075)	0.005	-0.161(0.075)	0.034
UD*CT					0.237 (0.072)	0.001			0.231 (0.071)	0.001
UD*AD							-0.188(0.071)	600.0	-0.181(0.069)	0.010
T.	0.120		0.179		0.223		0.208		0.250	
R^2 adj	0.074		0.123		0.165		0.150		0.190	
F-statistic	2.615**		3.171**		3.857**		3.537**		4.165**	
Notes: $n = 203$, values in table are unstandardized regression coefficients. Standard errors are in parentheses	dardized regressic	ın coefficie	nts. Standard err	ors are in p	arentheses					

Table A6 Regressions of crisis-related cumulative abnormal returns (three-day CAH, alternative measurement of corporate transparency—two years before the crisis)	ited cumulative a	bnormal r	eturns (three-d	ay CAR, a	alternative meas	surement	ot corporate tra	ınsparenc	y—two years be	etore the
Variables	Model 1	p-value	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p-value
(Constant)	0.017(0.095)	0.861	-0.044(0.094)	0.779	-0.036(0.093)	0.702	-0.029(0.093)	0.755	-0.018(0.091)	0.840
Profitability	-0.165(0.073)	0.025	-0.167(0.071)	0.223	-0.152(0.070)	0.032	-0.164(0.070)	0.019	-0.148(0.069)	0.032
Tobin's Q	(620.0)900.0-	0.936	-0.014(0.077)	0.858	-0.032(0.076)	0.671	-0.027(0.076)	0.718	-0.049(0.075)	0.516
Leverage	-0.031(0.083)	0.703	-0.091(0.082)	0.272	-0.126(0.082)	0.129	-0.112(0.081)	0.168	-0.152(0.081)	0.062
Firm size	-0.009(0.084)	0.918	-0.036(0.082)	0.663	-0.022(0.081)	0.786	-0.034(0.080)	0.670	-0.019(0.079)	0.808
Number of fatalities	-0.200(0.072)	900.0	-0.161(0.070)	0.023	-0.166(0.070)	0.018	-0.175(0.069)	0.012	-0.181(0.068)	600.0
Product harm	-0.367(0.231)	0.113	-0.242(0.229)	0.293	-0.264(0.226)	0.245	-0.277(0.226)	0.221	-0.304(0.222)	0.172
Technical accidents	0.142(0.188)	0.452	0.104(0.183)	0.569	0.121(0.181)	0.503	0.097(0.180)	0.591	0.115(0.177)	0.518
Organizational misdeed	-0.023(0.191)	906.0	0.277(0.208)	0.186	0.201(0.207)	0.334	0.236(0.205)	0.250	0.151(0.204)	0.458
Return on industry assets	-0.101(0.076)	0.187	-0.133(0.077)	0.086	-0.152(0.076)	0.048	-0.138(0.076)	0.071	-0.158(0.075)	0.036
Market share	0.208(0.084)	0.014	0.283(0.084)	0.001	0.286(0.083)	0.001	0.284(0.083)	0.001	0.288(0.081)	0.000
Corporate transparency (CT)			-0.079(0.070)	0.261	-0.101(0.069)	0.147	(690.0)660.0-	0.151	-0.125(0.068)	690.0
Unrelated diversification (UD)			0.182(0.071)	0.011	0.235(0.073)	0.001	0.178(0.069)	0.011	0.235(0.071)	0.001
Attribution of knowledge deficiency (AD)			-0.206(0.076)	0.008	-0.165(0.077)	0.033	-0.214(0.075)	0.005	-0.170(0.075)	0.025
UD*CT					0.194(0.076)	0.011			0.211(0.074)	0.005
UD*AD							-0.201(0.071)	0.005	-0.216(0.070)	0.002
H	0.120		0.183		0.211		0.217		0.249	
R adj	0.074		0.127		0.152		0.158		0.189	
F-statistic	2.615**		3.264**		3.590**		3.716**		4.136**	

Notes: n = 203, values in table are unstandardized regression coefficients. Standard errors are in parentheses

Table A7 Regressions of crisis-related cumulative crisis)		bnormal r	eturns (three-da	y CAR, a	lternative meas	urement (abnormal returns (three-day CAR, alternative measurement of corporate transparency—three years before the	sparency	'—three years bo	efore the
Variables	Model 1	p <i>-value</i>	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p-value
Constant) 0.017 (0.095) 0.802 -0.043 (0.094) 0.645 -0.045 Profitability -0.165 (0.073) 0.239 -0.167 (0.071) 0.019 -0.155 Tobin's Q -0.006 (0.073) 0.239 -0.167 (0.077) 0.853 -0.029 Leverage -0.003 (0.083) 0.122 -0.009 (0.082) 0.274 -0.121 Firm size -0.003 (0.084) 0.881 -0.037 (0.082) 0.027 -0.014 (0.077) Number of fatalities -0.200 (0.072) 0.006 -0.158 (0.070) 0.224 -0.158 (0.070) Product harm -0.200 (0.072) 0.006 -0.158 (0.070) 0.226 -0.158 (0.070) Product harm -0.367 (0.231) 0.140 -0.243 (0.229) 0.220 -0.158 (0.070) Product harm -0.367 (0.231) 0.140 -0.243 (0.229) 0.290 0.170 (0.025) Peturn on industry assets -0.023 (0.191) 0.772 0.280(0.208) 0.179 (0.070) 0.150 (0.070) Orphorate transparency (CT) 0.006 (0.084) 0.074 0.026 (0.070) 0.1	0.017 (0.095) -0.165 (0.073) -0.006 (0.079) -0.0031 (0.083) -0.009 (0.084) -0.367 (0.231) -0.023 (0.191) -0.023 (0.191) -0.101 (0.076) 0.120 0.120 0.074 2.615***	0.802 0.239 0.974 0.122 0.881 0.006 0.140 0.524 0.772 0.165	-0.043 (0.094) -0.167 (0.071) -0.014 (0.077) -0.003 (0.082) -0.033 (0.081) -0.158 (0.070) -0.243 (0.229) 0.097 (0.183) 0.280 (0.077) 0.280 (0.004) 0.280 (0.007) 0.184 (0.071) -0.092 (0.070) 0.184 (0.071) -0.092 (0.070) 0.185 0.185 0.129 3.305**	0.645 0.019 0.853 0.274 0.026 0.290 0.79 0.078 0.001 0.000	-0.042 (0.093) -0.155 (0.070) -0.029 (0.076) -0.121 (0.073) -0.158 (0.070) -0.257 (0.227) 0.111 (0.181) 0.223 (0.027) 0.279 (0.083) -0.150 (0.077) 0.222 (0.077) 0.222 (0.077) 0.164 (0.076) 0.205 0.146 3.462** entheses	0.652 0.028 0.701 0.146 0.859 0.025 0.0284 0.052 0.001 0.135 0.002 0.032	-0.027 (0.092) -0.165 (0.070) -0.028 (0.076) -0.111 (0.081) -0.031 (0.080) -0.173 (0.069) -0.278 (0.225) 0.089(0.180) 0.237 (0.205) 0.237 (0.205) 0.280 (0.082) -0.197 (0.071) 0.218 0.197 (0.071) 0.218 0.159	0.767 0.019 0.019 0.174 0.697 0.019 0.028 0.069 0.001 0.132 0.010 0.000	-0.023 (0.091) -0.150(0.069) -0.049 (0.075) -0.151 (0.081) -0.008 (0.079) -0.173 (0.068) -0.300 (0.222) 0.104 (0.177) 0.160(0.224) 0.278(0.081) -0.156 (0.075) 0.226 (0.075) 0.226 (0.075) 0.226 (0.075) 0.226 (0.075) 0.228 (0.075) 0.228 (0.075) 0.228 (0.075) 0.228 (0.075)	0.798 0.030 0.511 0.064 0.921 0.012 0.0557 0.039 0.001 0.002 0.002 0.002
Note: $n = 203$, values in table are unstand	lardized regressior	coefficien	ts. Standard errors	s are in paı	rentheses					

Table A8 Regressions of crisis-related cumulat	ed cumulative al	bnormal re	eturns (three-da	y CAR, ad	live abnormal returns (three-day CAR, add the Tenure in Stock Market as a control variable)	Stock Ma	ırket as a contro	ol variable)		
Variables	Model 1	p-value	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p-value
(Constant)	0.014(0.095)	0.861	-0.043(0.094)	0.649	-0.037(0.092)	0.687	-0.028(0.093)	0.765	-0.022(0.091)	0.805
Tenure in stock market	0.057(0.073)	0.434	0.039(0.071)	0.585	0.025(0.069)	0.721	0.037(0.070)	0.596	0.023(0.068)	0.732
Profitability	-0.164(0.073)	0.026	-0.166(0.071)	0.021	-0.151(0.070)	0.031	-0.164(0.070)	0.020	-0.150(0.068)	0.030
Tobin's Q	-0.003(0.079)	0.967	-0.013(0.077)	0.869	-0.034(0.076)	0.651	-0.026(0.076)	0.737	-0.046(0.075)	0.535
Leverage	-0.044(0.084)	0.599	-0.095(0.084)	0.257	-0.139(0.083)	0.094	-0.117(0.083)	0.159	-0.159(0.082)	0.053
Firm size	-0.019(0.085)	0.825	-0.044(0.083)	0.595	-0.033(0.081)	0.679	-0.044(0.081)	0.592	-0.033(0.079)	0.676
Number of fatalities	-0.193(0.072)	0.008	-0.157(0.071)	0.029	-0.166(0.070)	0.018	-0.170(0.070)	0.016	-0.179(0.068)	0.010
Product harm	-0.350(0.232)	0.132	-0.225(0.231)	0.332	-0.240(0.224)	0.289	-0.258(0.227)	0.259	-0.271(0.222)	0.223
Technical accidents	0.153(0.189)	0.421	0.108(0.184)	0.558	0.160(0.181)	0.376	0.099(0.181)	0.586	0.150(0.177)	0.399
Organizational misdeed	-0.030(0.192)	0.878	0.256(0.209)	0.222	0.176(0.205)	0.393	0.216(0.206)	0.294	0.139(0.202)	0.491
Return on industry assets	-0.110(0.077)	0.156	-0.129(0.077)	960.0	-0.148(0.076)	0.052	-0.133(0.076)	0.081	-0.151(0.074)	0.043
Marketshare	0.210(0.084)	0.013	0.282(0.084)	0.001	0.292(0.082)	0.000	0.284(0.083)	0.001	0.294(0.081)	0.000
Corporate transparency (CT)			-0.051(0.069)	0.462	-0.063(0.068)	0.354	-0.077(0.069)	0.265	-0.087(0.067)	0.194
Unrelated diversification (UD)			0.178(0.071)	0.013	0.244(0.072)	0.001	0.174(0.070)	0.014	0.238(0.071)	0.001
Attribution of knowledge deficiency (AD)			-0.206(0.076)	0.008	-0.154(0.076)	0.045	-0.214(0.075)	0.005	-0.163(0.075)	0.031
UD*CT					0.235(0.072)	0.001			0.229(0.071)	0.001
UD*AD							-0.201(0.071)	0.005	-0.195(0.070)	900.0
2	0.123		0.182		0.225		0.215		0.257	
R ² adj	0.072		0.121		0.163		0.152		0.193	
F-statistic	2.428**		2.983**		3.629**		3.412**		4.011**	

Note: n = 203, values in table are unstandardized regression coefficients. Standard errors are in parentheses

Table A9 Regressions of crisis-related cumulative abnormal returns (three-day CAR, add four dummy variables of corporate type as control variable)	ulative abnorma	l returns	(three-day CAF	۶, add fo	ur dummy varie	bles of o	corporate type a	s contro	ıl variable)	
Variables	Model 1	p- <i>value</i>	Model 2	p-value	Model 3	p-value	Model 4	p-value	Model 5	p- <i>value</i>
(Constant)	-0.025 (0.133)	0.851	0.000 (0.131)	1.000	0.005 (0.128)	0.971	0.025 (0.129)	0.845	0.029 (0.126)	0.819
Pharmacy	0.071 (0.198)	0.719	-0.152(0.206)	0.461	-0.140(0.201)	0.486	-0.161(0.202)	0.456	-0.149(0.197)	0.451
Manufacturing of chemical materials and products	-0.240(0.266)	0.367	-0.295(0.260)	0.258	-0.324(0.254)	0.204	-0.305(0.256)	0.235	-0.332(0.250)	0.185
Wine, beverage and refined tea manufacturing	0.345(0.421)	0.413	0.250 (0.419)	0.551	0.191 (0.408)	0.641	0.194 (0.412)	0.637	0.139 (0.402)	0.730
Capital market services	0.167 (0.819)	0.838	0.471 (0.798)	0.556	0.682 (0.780)	0.383	0.253 (0.788)	0.748	0.467(0.771)	0.545
Profitability	-0.188(0.081)	0.022	-0.192(0.079)	0.016	-0.185(0.077)	0.018	-0.180(0.078)	0.022	-0.174(0.076)	0.023
Tobin's Q	-0.007 (0.080)	0.928	-0.006 (0.078)	0.940	-0.025(0.077)	0.745	-0.022(0.077)	0.781	-0.040(0.076)	0.602
Leverage	-0.037(0.084)	0.656	-0.109(0.084)	0.199	-0.159(0.083)	0.058	-0.127(0.083)	0.128	-0.176(0.082)	0.034
Firm size	-0.007 (0.088)	0.934	-0.038 (0.086)	0.655	-0.023(0.084)	0.783	-0.045(0.084)	0.597	-0.030(0.082)	0.720
Number of fatalities	-0.196(0.073)	0.007	-0.152(0.071)	0.035	-0.160(0.069)	0.022	-0.167(0.070)	0.019	-0.174(0.069)	0.012
Product harm	-0.366 (0.238)	0.125	-0.166(0.239)	0.487	-0.184(0.233)	0.431	-0.203(0.235)	0.389	-0.219(0.229)	0.341
Technical accidents	0.226 (0.206)	0.275	0.123 (0.202)	0.545	0.185(0.198)	0.351	0.109(0.199)	0.585	0.170(0.195)	0.384
Organizational misdeed	-0.023(0.196)	906.0	0.247 (0.209)	0.241	0.166(0.206)	0.421	0.210 (0.206)	0.309	0.133 (0.202)	0.512
Return on industry assets	-0.168(0.107)	0.117	-0.167 (0.104)	0.108	-0.178(0.101)	0.079	-0.165(0.102)	0.107	-0.176(0.099)	0.078
Market share	0.205(0.093)	0.028	0.246(0.091)	0.008	0.251(0.089)	0.005	0.254(0.090)	0.005	0.258(0.087)	0.004
Corporate transparency (CT)			-0.070(0.073)	0.339	-0.083(0.071)	0.246	-0.096(0.072)	0.185	-0.108(0.071)	0.128
Unrelated diversification (UD)			0.203(0.073)	900.0	0.267 (0.073)	0.000	0.197(0.071)	900.0	0.260(0.072)	0.000
Attribution of knowledge deficiency (AD)			-0.219(0.078)	900.0	-0.165(0.078)	0.035	-0.225(0.077)	0.004	-0.173(0.076)	0.025
UD*CT					0.240 (0.073)	0.001			0.233(0.071)	0.001
UD*AD							-0.198(0.072)	0.007	-0.190(0.070)	0.007
24	0.127		0.193		0.238		0.225		0.268	
R ² adj	0.062		0.119		0.164		0.149		0.191	
F-statistic	1.951**		2.603**		3.196**		2.964**		3.517**	

Note: n = 203, values in table are unstandardized regression coefficients. Standard errors are in parentheses